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Abstract 
 
Connexin 30 (Cx30), a member of the large gap junction protein family, plays a role in 
the homeostasis of the epidermis and inner ear through gap junctional intercellular 
communication (GJIC).  Here, we investigated four autosomal dominant Cx30 gene 
mutations linked to hearing loss and/or various skin diseases.  First, the T5M mutant 
linked to non-syndromic hearing loss formed functional gap junction channels and 
hemichannels, similar to wild-type Cx30.  The V37E mutant associated with keratitis-
ichthyosis-deafness (KID) syndrome was retained in the endoplasmic reticulum (ER) and 
significantly induced unfolded protein response (UPR)-mediated apoptosis.  The loss-of-
function G59R mutant linked to Vohwinkel and Bart-Pumphrey syndromes was retained 
primarily in the Golgi apparatus.  Lastly, the Clouston syndrome-linked A88V mutant 
significantly induced apoptosis, primarily through an UPR-independent mechanism.  
Collectively, we discovered that four unique Cx30 mutants cause disease through 
different mechanisms, highlighting the overall complexity of connexin-linked diseases 
and the importance of GJIC in disease prevention.   
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Chapter 1  
1 Literature Review 
1.1 Connexins and Gap Junctions 
Connexins (Cx) are polytopic integral membrane proteins that make up the gap junction 
protein family, of which there are 21 members in humans (Sohl and Willecke, 2003; Sohl 
and Willecke, 2004).  Connexins are named according to their molecular weights in 
kilodaltons (kDa) and are categorized into α, β, γ, δ and ε subgroups based on sequence 
homology (Cruciani and Mikalsen, 2006; Mese et al., 2007; Sonntag et al., 2009).  The 
polypeptide backbone of a connexin protein spans the cell membrane four times, forming 
two extracellular loops and one cytoplasmic loop, with both the amino and carboxy 
termini extending into the cytoplasm of the cell (Falk et al., 1997; Kumar and Gilula, 
1996).  While all connexins share a similar structural topology and highly conserved 
transmembrane and extracellular domains (Maeda et al., 2009; Mese et al., 2007), the 
length of the cytoplasmic loop and carboxy terminal tail varies between connexin family 
members (Goodenough et al., 1996; Saez et al., 2003; White and Bruzzone, 1996).   
Six connexins oligomerize to form a connexon, which can be termed homomeric or 
heteromeric according to whether it is composed of one or more connexin isoforms, 
respectively (Mese et al., 2007).  At the plasma membrane, a connexon can act as a 
hemichannel to allow for communication between the cytoplasm of the cell and its 
extracellular environment, or dock with a connexon from an apposing cell to form a 
functional intercellular communication channel (Laird, 2006).  These extensively 
characterized channels, known as gap junction channels, are termed homotypic or 
heterotypic depending on whether they are composed of identical or different connexons 
(Mese et al., 2007).  The ability of connexins to co-oligomerize and form mixed channels 
ultimately depends on the connexin expression profile of each cell type as well as the 
compatibility of the connexins.   
Connexins are temporally and spatially expressed in almost every cell type and tissue in 
the human body (Goodenough et al., 1996; Saez et al., 2003), and Cx43 (encoded by the 
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GJA1 gene) is the most ubiquitous, as it is endogenously expressed in over 35 distinct 
tissue types (Laird, 2006) including the heart, skin, brain and bone (Darrow et al., 1995; 
Dermietzel et al., 1989; Jones et al., 1993; Zhang et al., 1995).  In addition, most cell 
types express multiple connexins and have overlapping connexin expression profiles 
(Laird, 2006; White and Bruzzone, 1996).   For example, cardiomyocytes express Cx40, 
Cx43 and Cx45 (Coppen et al., 1999; Gourdie et al., 1993), and keratinocytes have been 
reported to express at least 10 different connexins including Cx26, Cx30, Cx31 and Cx43 
(Di et al., 2005; Di et al., 2001).  Mixed channels composed of Cx40 and Cx43 exist in 
the myocardium of the heart (Cottrell et al., 2001; Valiunas et al., 2000), while Cx26 and 
Cx30 mixed channels exist in the cochlea (Ahmad et al., 2003; Forge et al., 2003b; Sun et 
al., 2005; Yum et al., 2007).  Mixed channels often exhibit distinct properties unique 
from their homomeric/homotypic counterparts (Beyer et al., 2001), or may be dominated 
by the properties of one of the contributing connexins (Ayad et al., 2006; Desplantez et 
al., 2004; Martinez et al., 2002).  Importantly, not all co-expressed connexins are capable 
of co-oligomerizing to form mixed channels, as has been previously reported for Cx26 
and Cx43 (Gemel et al., 2004). 
1.2 Gap Junctional Intercellular Communication 
Gap junction channels connect neighbouring cells to establish a direct cell-cell 
communication system through which electrical signals, ions and various hydrophilic 
cellular metabolites smaller than 1000 Da can pass (Alexander and Goldberg, 2003).  
This complex exchange process is known as gap junctional intercellular communication 
(GJIC), and gap junction channels aggregate into clusters on the plasma membrane, 
known as gap junction plaques, to allow for extensive GJIC between 2 apposing cells 
(Laird, 2006).  Effective GJIC contributes to overall tissue maintenance and homeostasis, 
as it plays important roles in proliferation, differentiation and apoptosis, as well as 
growth and development (Choudhry et al., 1997; Kameritsch et al., 2013; Krysko et al., 
2005; Langlois et al., 2007; McLachlan et al., 2007; White et al., 2007).  For example, in 
wound healing, connexins are differentially expressed around the wound edge to regulate 
particular types of GJIC, altering the transjuctional molecules thought to be necessary to 
promote wound closure (Churko and Laird, 2013).   
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Two important secondary messengers that mediate intercellular signalling, cyclic 
adenosine monophsophate (cAMP) and inositol 1,4,5-trisphosphate (IP3), permeate 
through most gap junctions, including those composed of Cx26, Cx32 and Cx43 (Bedner 
et al., 2006; Bedner et al., 2003; Niessen et al., 2000; Niessen and Willecke, 2000) as 
well as some heteromeric channels including Cx26/Cx30 and Cx43/Cx46 (Qu and Dahl, 
2002; Zhang et al., 2005).  However, the relative permeabilities of each channel to these 
molecules are variable.  This is supported by Cx32 and Cx43 permeability studies, 
whereby Cx43 channels are 300-fold more efficient at mediating adenosine triphosphate 
(ATP) transfer than Cx32 channels, while adenosine permeates through Cx32 channels 
10-fold better than through Cx43 channels (Goldberg et al., 1999; Goldberg et al., 2002).  
While the differential permeabilities of gap junction channels to certain molecules are 
dictated partly by limiting pore size, selectivity is also based on molecular size, 
flexibility, charge and charge distribution (Harris, 2007; Kwon et al., 2011; Maeda et al., 
2009).   
1.3 Hemichannels 
In addition to forming gap junction channels, connexons have also been reported to act at 
the cell surface as undocked single membrane hemichannels, facilitating communication 
between the intra/extracellular environments.  Hemichannels remain closed under 
physiological conditions, but open in response to changes in intra/extracellular ion 
concentrations, transmembane voltage, mechanical strain and post-translational 
modifications including phosphorylation (Wang et al., 2013).  Hemichannel permeability 
is dictated by similar properties as for gap junction channels, as signalling molecules pass 
differentially through specific channels.  For example, nicotinamide adenine dinucleotide 
(NAD
+
) and prostaglandin E2 have been reported to pass through Cx43 hemichannels 
(Bruzzone et al., 2001; Siller-Jackson et al., 2008), while ATP can permeate through 
Cx26, Cx30 or Cx43 homotypic (Essenfelder et al., 2004; Gomes et al., 2005; Tran Van 
Nhieu et al., 2003), as well as Cx26/Cx30 heterotypic hemichannels (Anselmi et al., 
2008; Majumder et al., 2010).  These molecules act on neighbouring cells in a paracrine 
fashion, triggering downstream cellular signalling pathways in many tissues (Wang et al., 
2013).  In the developing cochlea, ATP acts on purinergic receptors of inner hair cells to 
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elevate Ca
2+
 levels and maintain the survival of the spiral ganglion neurons (Tritsch et al., 
2007).  In addition, abnormal hemichannel activity has been implicated in a number of 
diseases caused by connexin gene mutations, including Charcot-Marie-Tooth disease 
(CMTX) (Liang et al., 2005), Clouston syndrome (Essenfelder et al., 2004) and keratitis-
ichthyosis-deafness (KID) syndrome (Levit et al., 2012).  It has also been reported that 
ATP release through leaky hemichannels may act in a paracrine fashion to facilitate cell 
death (Wang et al., 2013). 
1.4 Connexin Life Cycle 
Connexin proteins have relatively short half-lives of only a few hours, highlighting the 
importance of rapid gap junction turnover (Beardslee et al., 1998; Fallon and 
Goodenough, 1981; Laird et al., 1991).  This continuous process is mediated by connexin 
synthesis and oligomerization, trafficking to the cell surface, channel assembly, 
internalization and degradation; processes that can all be regulated to allow cells to 
respond to many changes in physiological conditions (Laird, 2006).  Connexins typically 
follow the traditional integral membrane protein secretory pathway to the cell surface, as 
they are co-translationally inserted in the endoplasmic reticulum (ER), pass through the 
Golgi apparatus and traffic to the cell surface (Laird, 2006; Musil and Goodenough, 
1993).  Protein folding occurs in the oxidizing environment of the ER with the assistance 
of a number of chaperone proteins and folding enzymes (Kleizen and Braakman, 2004), 
and it has been suggested that isomerases facilitate the formation of low energy disulfide 
bonds important for specific connexin conformation (Laird, 2006).  Oligomerization has 
been reported to occur in the ER for a number of connexins including Cx32 (Das Sarma 
et al., 2002; Maza et al., 2005), but later in the trans-Golgi network for Cx43 and Cx46 
(Koval et al., 1997; Musil and Goodenough, 1993).  It has been previously suggested that 
following the oligomerization process, connexons are transported via microtubules to the 
cell surface in a closed state (Laird, 2006).  An exception to this traditional secretory 
pathway may be Cx26, as it has also been reported to be post-translationally inserted into 
the ER (Ahmad and Evans, 2002) as well as directly inserted into the plasma membrane 
(Zhang et al., 1996), although these studies have not been widely accepted.  A more 
recent study demonstrated that Cx26 follows the same secretory pathway as Cx43, 
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passing through the Golgi apparatus on the way to the cell surface, as gap junction 
assembly was sensitive to treatment with ER-Golgi protein transport blocker, brefeldin A 
(Thomas et al., 2005). 
Once embedded in the plasma membrane, connexons can act as undocked hemichannels, 
or form gap junction channels that mediate GJIC (Laird, 2006).  Gap junction plaque 
formation is a highly dynamic process by which newer gap junction channels form 
around the outer edges of an existing plaque, as demonstrated for Cx43 (Gaietta et al., 
2002).  Aged gap junction channels in the center of the plaque are destined for 
internalization by endosomal pathways or as double-membrane annular junctions termed 
connexosomes (Laird, 2006).  Once internalized, gap junctions and connexins may be 
degraded by lysosomes or proteosomes, as there is evidence supporting both pathways 
(Laing et al., 1997; Qin et al., 2003).  However, one study reported that Cx43 could be 
recycled back to the cell surface to participate once again in gap junction formation 
(VanSlyke and Musil, 2005). 
1.5 Epidermal Differentiation 
The epidermis is comprised mainly of keratinocytes, which continuously differentiate to 
form multiple stratified epidermal layers that maintain the integrity of the skin (Cartlidge, 
2000).  The skin acts as a physical barrier to protect against pathogen invasion, physical 
and chemical insults, as well as solute and water loss (Proksch et al., 2008).  The 
outermost layer of the epidermis forms this specialized protective barrier, and is 
generated by the progressive differentiation of keratinocytes in the innermost layer, the 
stratum basale (Cartlidge, 2000).  The stratum basale separates the epidermis from the 
underlying dermis and contains keratinocyte stem cells that replenish the basal 
keratinocyte population as they differentiate to form the suprabasal layers; the stratum 
spinosum and stratum granulosum (Kretz et al., 2004).  The large keratinocytes in the 
stratum spinosum are involved in the synthesis and production of a number of large 
keratin molecules (Fuchs and Green, 1980), while granular keratinocytes produce lipids 
that contribute to the hydrophobic barrier of the stratum corneum (Proksch et al., 2008).  
Keratinocytes then undergo terminal differentiation and programmed cell death to form 
the outer epidermal layer, a process that shares some similarities with apoptosis, 
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including morphological changes and fragmented nuclei, but occurs through a distinct 
mechanism (Lippens et al., 2005).  The dead cells residing in the stratum corneum 
maintain their enzymatic activity (Churko and Laird, 2013), differentiating them from 
apoptotic cells.  Finally, as subcorneal keratinocytes continue to differentiate, cellular 
connections in the outermost corneal layers deteriorate and the outer layer of the 
epidermis is sloughed off (Cartlidge, 2000). 
1.6 Connexins in the Epidermis 
Connexins play an important role in the proliferation and differentiation of the epidermis 
(Choudhry et al., 1997; Langlois et al., 2007; Risek et al., 1992).  Human epidermal 
keratinocytes contain messenger RNA (mRNA) for at least 10 different connexins, and 
many are differentially expressed at the protein level throughout the epidermal strata, 
excluding the stratum corneum (Di et al., 2001; Kretz et al., 2004).  Connexin expression 
overlaps in the layers of the epidermis, however, distinct subpopulations of keratinocytes 
express particular connexins.  For example, Cx26 is expressed in the basal and granular 
layers, Cx30 and Cx45 are localized mainly to the granular layer with some expression in 
the stratum spinosum, and Cx40 is uniformly expressed across both suprabasal layers (Di 
et al., 2005; Di et al., 2001).  Rat epidermal keratinocytes (REKs) express mRNA for a 
similar number of connexins (Maher et al., 2005), and adult rat epidermis exhibits the 
overlapping expression of Cx26, Cx31, Cx31.1, Cx37 and Cx43 (Goliger and Paul, 1994; 
Risek et al., 1992).  In the epidermis of all mammalian species, complex connexin 
expression facilitates GJIC within an epidermal layer as well as across different 
epidermal layers (Richard, 2000), forming intricate communication systems to regulate 
keratinocyte proliferation and differentiation.  Furthermore, connexin mutations that 
disregulate epidermal GJIC have been reported to result in a number of hyperproliferative 
and mutilating skin diseases (Bakirtzis et al., 2003; Bondeson et al., 2006; Jan et al., 
2004; Smith et al., 2002; Tattersall et al., 2009).  
1.7 Hearing and Sound Transduction 
Hearing is a complex process involving the transmission of sounds from the outer ear to a 
compartmentalized structure in the inner ear known as the cochlea.  Middle ear bones 
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convert sound waves into pressure waves that travel through the cochlea, along a basilar 
membrane where sensory hair cells and supporting cells of the Organ of Corti are located 
(Fettiplace and Hackney, 2006).  The cochlea contains two fluid-filled compartments, 
which hold the perilymph or endolymph, the latter of which is high in K
+
 (Kikuchi et al., 
2000), establishing the endocochlear potential (EP) necessary for sensory transduction 
(Wangemann, 2006).  When an acoustic stimulus activates hair cells, endolymphatic K
+
 
rushes into them, relaying important information about the sound to the brain (Fettiplace 
and Hackney, 2006).  K
+
 is then released into the extracellular space of the Organ of 
Corti, and two gap junction systems, known as the epithelial and connective tissue gap 
junction networks, play important roles in the recycling of K+ back to the endolymph 
(Hibino and Kurachi, 2006; Kikuchi et al., 2000) to maintain the EP (Hibino and Kurachi, 
2006; Kikuchi et al., 2000; Wangemann, 2006). 
1.8 Connexins in the Inner Ear 
To date, five connexins, including Cx26, Cx29, Cx30, Cx31 and Cx43, have been 
identified in the epithelial and connective tissue gap junction networks of the mature 
mammalian cochlea, with evidence of overlapping expression (Nickel and Forge, 2008).  
For example, while Cx31 expression is restricted to the connective tissue network (Xia et 
al., 2000), Cx26, Cx30 and Cx43 are expressed in both (Lautermann et al., 1998).  
Importantly, Cx26 and Cx30 are the most predominantly expressed connexins in the 
inner ear (Hoang Dinh et al., 2009), and many studies support the notion that they are 
capable of forming functional mixed channels (Ahmad et al., 2003; Forge et al., 2003a; 
Forge et al., 2003b; Sun et al., 2005; Zhao and Santos-Sacchi, 2000).  Mutations in these 
two connexins account for over half of all reported cases of inherited pre-lingual non-
syndromic hearing loss (Chang et al., 2009; Schutz et al., 2010; Wang et al., 2011), which 
is classified as hearing loss in the absence of other disease manifestations.  While it has 
been suggested that connexin mutations commonly affect K
+
 recycling due to their 
expression in cochlear gap junction networks, evidence also supports that mutations 
cause defects in biochemical or metabolic coupling rather than ionic coupling 
(Beltramello et al., 2005; Schutz et al., 2010; Zhang et al., 2005).  Furthermore, Cx30 
knock out (Gjb6
-/-
, referred to as Cx30
-/- 
in this thesis) and epithelial network-Cx26 
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ablated mice were found to be deaf, as the loss of these connexins resulted in epithelium 
degeneration and loss of EP.  However, the cochlea and vestibular organs were normally 
shaped, suggesting that connexins may not play essential structural roles in cochlear 
development (Cohen-Salmon et al., 2002; Teubner et al., 2003).   
1.9 Connexins in Disease 
Connexin mutations have been linked to a number of distinct diseases.  Oculodentodigital 
dysplasia (ODDD) is a rare disease distinctly associated with Cx43 mutations, and to 
date, over sixty five mutations have been identified (Huang et al., 2013; Paznekas et al., 
2009).  Since Cx43 is ubiquitously expressed, this disease manifests in a number of ways 
and is characterized by craniofacial abnormalities, syndactyly of the digits, as well as 
ophthalmic and dental abnormalities (Paznekas et al., 2003).  In addition, hearing loss 
and distinct hyperproliferative skin disorders have been associated with mutations in 
Cx26, Cx30, Cx30.3 and Cx31 (Laird, 2006).  Mutations in both Cx30.3 and Cx31 result 
in erythrokeratoderma variabilis (EKV) (Richard et al., 2003; Tattersall et al., 2009), 
while hidrotic ectodermal dysplasia (HED), also known as Clouston syndrome, is 
distinctly caused by Cx30 mutations, of which there have been four identified to date 
(Baris et al., 2008; Common et al., 2002; Smith et al., 2002).  Other diseases including 
KID, Vohwinkel and Bart-Pumphrey syndromes, previously linked to Cx26 mutations 
(Lee and White, 2009), have also been associated with mutations in the highly 
homologous Cx30 family member (Jan et al., 2004; Nemoto-Hasebe et al., 2009), 
highlighting the heterogeneity of these particular connexin-linked skin diseases.  
Furthermore, many of these hyperproliferative disorders are associated with hearing loss, 
and to date, approximately eight Cx30 mutations and over one hundred Cx26 mutations 
have been linked to various forms of hearing loss, including non-syndromic hearing loss 
(Baris et al., 2008; Nemoto-Hasebe et al., 2009; Wang et al., 2011; Zhang et al., 2005). 
1.10 Cx30 Mutations Linked to Various Skin Diseases and 
Non-Syndromic Hearing Loss 
Cx30, encoded by the GJB6 gene, is an understudied member of the connexin protein 
family, and is highly expressed in the mammalian epidermis, inner ear and brain (Dahl et 
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al., 1996; Scott et al., 2012).  To date, seven autosomal dominant missense mutations 
have been identified in the Cx30 gene that result in skin disease, hearing loss or a 
combination of both (Fig. 1.1).  Clouston syndrome linked distinctly to Cx30 mutations 
(Lamartine et al., 2000a), is a rare autosomal dominant disease first described by 
Clouston (1929).  This disease is characterized mainly by nail deformities and increased 
susceptibility to nail infections, partial to complete hair loss and palmoplantar 
hyperkeratosis (PPK), which includes thickening of the skin on the palms of the hands 
and soles of the feet (Ando et al., 1988; Pierard et al., 1979; Rajagopalan and Tay, 1977).  
Clouston also reported that some patients had craniofacial abnormalities, ocular 
problems, as well as clubbed fingers and toes (Fraser and Der Kaloustian, 2001), while 
hearing loss and abnormal cardiac findings have also been reported in some cases 
(Christianson and Fourie, 1996; Lamartine et al., 2000b).  Clouston syndrome affects 
approximately 1 in 100,000 people, and while the disease has affected families of 
different ethnic origins (Christianson and Fourie, 1996; Kibar et al., 2000; Lamartine et 
al., 2000b; Rajagopalan and Tay, 1977), it is most prevalent in the French-Canadian 
population due to a founder effect (Kibar et al., 2000).  This loss of genetic variation 
occurs when a small number of individuals from a large population segregate to form a 
new population.  Four particular Cx30 mutations have been identified, including G11R 
(11
th
 amino acid - glycine to arginine substitution) (Zhang et al., 2003), V37E (37
th
 amino 
acid - valine to glutamic acid) (Smith et al., 2002), D50N (50
th
 amino acid - aspartic acid 
to asparagine) (Baris et al., 2008) and A88V (88
th
 amino acid - alanine to valine) 
(Lamartine et al., 2000b).  Interestingly, one patient harbouring the V37E mutant 
exhibited symptoms of KID syndrome, which is characterized by a similar skin 
phenotype as Clouston syndrome, but also includes erythrokeratoderma, hearing loss and 
vascularising keratitis (Jan et al., 2004).  The V37E and D50N mutations have been 
identified in sporadic cases of Clouston syndrome (Baris et al., 2008; Smith et al., 2002), 
meaning these mutations appear in a more isolated and scattered fashion, while the G11R 
and A88V mutations are most common (Lamartine et al., 2000b) and have become the 
mutants of most research focus.  It has been reported that while the G11R and A88V 
mutants were unable to form gap junctions at the cell surface of HeLa cells and 
keratinoctyes (Common et al., 2002), they exhibited abnormal hemichannel activity, as  
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Figure 1.1:  Hearing loss- and skin disease-linked Cx30 mutations 
To date, seven Cx30 mutants have been reported to cause various skin diseases, hearing 
loss or a combination of both.  These single amino acid substitution mutations are found 
within the 1st half of the Cx30 amino acid polypeptide. 
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shown by the release of ATP and subsequent cell death (Essenfelder et al., 2004).  The 
amino terminal and 2
nd
 transmembrane connexin domains, where G11R and A88V are 
located, have been suggested to play important roles in stabilizing intra-connexin 
interactions that dictate channel permeability, as has been reported for Cx26 (Maeda et 
al., 2009).  Mutations in these critical domains may result in open hemichannels, 
increasing their permeability and causing them to leak important cellular molecules.  
Furthermore, premature cell death as a result of abnormal hemichannel activity may 
explain the PPK associated with Clouston syndrome, however further studies are 
necessary to determine how these particular point mutations are related to the 
development of this disease. 
A novel G59R mutation (59
th
 amino acid - glycine to asparagine) has been recently 
identified in the Cx30 gene, and the patient with this mutation presented with symptoms 
resembling Bart-Pumphrey and Vohwinkel syndromes (Nemoto-Hasebe et al., 2009).  
Bart-Pumphrey syndrome is characterized by hearing loss, knuckle pads, PPK and 
leukonychia (white discolouration of the nails) (Bart and Pumphrey, 1967), while 
Vohwinkel syndrome symptoms include mutilating keratoderma and the formation of 
constricting fibrous bands around fingers and toes, which result in their spontaneous 
auto-amputation (pseudoainhum) (Goldfarb et al., 1985).  The patient harbouring the 
G59R Cx30 mutation experienced knuckle pads, severe hearing loss, mild PPK, and 
pseudoainhum of the toes (Nemoto-Hasebe et al., 2009).  These two diseases have never 
before been linked to Cx30 mutations, as they are more frequently caused by mutations in 
Cx26 (Alexandrino et al., 2005; Bondeson et al., 2006; Maestrini et al., 1999; Marziano 
et al., 2003; Richard et al., 2004), thus the G59R Cx30 mutant remains poorly 
understood.  However, D66H and G59A Cx26 mutants linked to Vohwinkel syndrome 
are localized mainly to intracellular compartments and are non-functional (Marziano et 
al., 2003; Thomas et al., 2004).  
In addition to skin abnormalities, two particular Cx30 gene mutations have been linked to 
non-syndromic hearing loss (Grifa et al., 1999; Wang et al., 2011), and both act through 
distinct mechanisms.  Wang et al. (2011) demonstrated that the A40V mutant (40
th
 amino 
acid - alanine to valine) was retained in the ER and the Golgi apparatus, rendering the 
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mutant unable to form gap junction channels at the plasma membrane. This amino acid is 
highly conserved among many connexins including Cx26, Cx30, Cx30.3, Cx31 and 
Cx32, and is located in the 1
st
 transmembrane domain suggested to be important for 
protein folding and stability (Maeda et al., 2009).  This mutant may negatively affect 
overall K
+
 recycling in the inner ear as it obviously impairs the formation of gap junction 
channels (Wang et al., 2011).  Another mutation reported to affect K
+
 recycling through 
Cx30-based gap junctions is the T5M mutation (5
th
 amino acid – threonine to methionine) 
(Grifa et al., 1999), however its functional capacity remains controversial.  Although the 
T5M mutation does not impair the trafficking of the protein to the plasma membrane of 
HeLa cells or keratinocytes (Common et al., 2002; Zhang et al., 2005), studies have 
demonstrated its inability to pass electrical currents and small molecules (Common et al., 
2002; Grifa et al., 1999).  As previously discussed, more recent research has suggested 
that T5M-based channels may only be defective in their capacity to pass larger 
molecules, indicating that metabolic coupling and not K
+ 
recycling impairment may be 
the cause of hearing loss related to this mutant (Schutz et al., 2010; Zhang et al., 2005).  
Importantly, the amino terminal domain has been suggested to play a critical role in 
channel gating and permeability (Maeda et al., 2009), and the T5M substitution may 
change which molecules or ions can permeate through the gap junction channels.  
Nevertheless, further characterization of all Cx30 mutants is critical for the mechanistic 
understanding of how each mutant is linked to a specific disease.  In my thesis I will 
focus on four mutants (T5M, V37E, G59R and A88V) that cause skin disease and/or 
hearing loss.   
1.11 Apoptosis 
Apoptosis, also known as programmed cell death, is a highly regulated and complex 
three-stage process, that results in the eventual degradation and removal of damaged cells 
(Abraham and Shaham, 2004; Elmore, 2007; Saraste and Pulkki, 2000).  In contrast to 
this controlled process, necrosis is an uncontrolled form of cell death characterized by 
cellular swelling, degradation of subcellular organelles, rupture of the cell membrane and 
leakage of intracellular components into the extracellular environment (Krysko et al., 
2008).  The initiation and commitment stages of apoptosis involve the activation/cleavage 
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of  a number of proteases called caspases, which work together to subsequently cleave 
cellular substrates; characteristic of the degradation phase (Saraste and Pulkki, 2000). 
During the last apoptotic stage, a number of distinct morphological changes become 
visible.  These include shrinkage of the cell as structural proteins are cleaved (Brown et 
al., 1997; Orth et al., 1996; Wen et al., 1997), activation of DNase enzymes which 
degrade DNA (Liu et al., 1997; Sakahira et al., 1998), fragmentation of the nucleus, cell 
detachment and the formation of apoptotic bodies which are later phagocytosed by 
neighbouring cells (Elmore, 2007; Kerr et al., 1972).  The activation of caspases has been 
reported to occur mainly through two well-established apoptotic pathways, the extrinsic 
death receptor-mediated pathway and the intrinsic mitochondrial-mediated pathway 
(Elmore, 2007).  In the intrinsic pathway, death stimuli activate a number of signalling 
cascades that directly or indirectly result in the release of cytochrome c from the 
mitochrondria, triggering the activation of caspase-9.  In the extrinsic pathway, a number 
of death ligand-receptor interactions (Ashkenazi and Dixit, 1998; Marsters et al., 1998) 
trigger the activation of caspase-8 (Elmore, 2007).  Both pathways specifically result in 
the downstream activation of caspase-3, which triggers the final degradation stage of 
apoptosis (Elmore, 2007).   
1.12 Connexins in Cell Death 
The role of connexins in cell survival and cell death is poorly understood, however 
studies suggest that connexins play critical roles in mediating the passage of survival and 
death signals between cells (Decrock et al., 2009b; Krysko et al., 2005; Vinken et al., 
2006).  In the epidermis, connexins play a role in differentiation-dependent programmed 
cell death known as cornification, which is distinct from apoptosis (Lippens et al., 2005), 
however connexins have also been implicated in apoptotic signalling.  In particular, GJIC 
has been suggested to relay pro-apoptotic signals to coupled cells in a connexin type-
dependent manner and increasing evidence suggests that hemichannels also play a role 
(Decrock et al., 2009a; Decrock et al., 2009b; Kalvelyte et al., 2003; Kameritsch et al., 
2013).  HeLa cells expressing Cx37, Cx40 or Cx43 were exposed to streptonigrin and α-
Fas, which respectively trigger the intrinsic and extrinsic apoptotic pathways, and 
apoptosis was significantly higher in Cx43-expressing cells compared to empty vector 
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controls and Cx37-expressing cells.  When gap junction function was inhibited with 
pharmacological agents, apoptosis was reduced in Cx43-expressing cells, providing 
evidence for the role of gap junctions in differentially mediating apoptotic signals 
(Kameritsch et al., 2013). 
Many disease-linked connexin mutations result in trafficking defects that prevent the 
formation of gap junctions at the plasma membrane (Common et al., 2002; Di et al., 
2002; Gottfried et al., 2002; Tattersall et al., 2009; Wang et al., 2011), while others alter 
gap junction channel or hemichannel function (Gerido et al., 2007; Grifa et al., 1999; 
Mese et al., 2011; Shao et al., 2012; Stong et al., 2006; Thomas et al., 2004).  
Additionally, a number of these mutations have been linked to cell death.  For example, 
Cx26 mutations linked to KID syndrome induce cell death as a result of abnormal 
hemichannel activity (Gerido et al., 2007; Lee et al., 2009; Mhaske et al., 2013; 
Montgomery et al., 2004; Stong et al., 2006; Terrinoni et al., 2010), where hemichannels 
are inappropriately gated open under normal physiological conditions.  In addition, G11R 
and A88V Cx30 mutants also exhibit leaky hemichannels, and released ATP may act on 
surrounding cells in a paracrine fashion to induce cell death (Essenfelder et al., 2004).  
When connexin mutations result in trafficking defects, mutant connexins are often 
retained in the ER or Golgi apparatus (Common et al., 2002; Tattersall et al., 2009; Wang 
et al., 2011).  In particular, the accumulation of mutant connexin proteins in the ER has 
previously been shown to induce cell death through an ER stress-mediated pathway, as 
reported for a number of Cx31 mutations linked to EKV (Di et al., 2002; He et al., 2005; 
Tattersall et al., 2009).  Further studies are necessary to dissect the mechanisms by which 
mutant connexins can induce cell death and ultimately cause disease.  
1.13 ER Stress and the Unfolded Protein Response 
The ER is a unique subcellular organelle that functions to synthesize and properly fold 
and modify newly synthesized proteins (Berridge, 2002).  The ER contains a number of 
chaperone proteins, including calreticulin and calnexin, that are involved in the quality 
control process (Hirsch et al., 2004).  Chaperone proteins aid in the process of protein 
packaging, and play an important role in sensing misfolded proteins, which they either 
attempt to fold, or target for degradation (Groenendyk and Michalak, 2005).  The 
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accumulation of persistently misfolded proteins in the ER triggers ER stress and an 
adaptive cellular response known as the unfolded protein response (UPR) (Groenendyk 
and Michalak, 2005; Malhotra and Kaufman, 2007; Rasheva and Domingos, 2009).  
Glucose regulated protein 78 (GRP78) is a luminal ER chaperone protein normally bound 
to three UPR sensors known as inositol requiring kinase 1 (IRE1), activating transcription 
factor 6 (ATF6) and double stranded RNA-activated protein kinase-like ER kinase 
(PERK) (Malhotra and Kaufman, 2007).  GRP78 directly binds misfolded proteins and 
results in the co-ordinated activation of the UPR upon releasing these sensors (Bertolotti 
et al., 2000; Shen and Prywes, 2005).  Activation of the IRE1 pathway primarily results 
in the induction of a number of genes involved in endoplasmic reticulum-associated 
degradation (ERAD), as well as an increase in lipid synthesis, which expands the size of 
the ER to accommodate new folding requirements (Berridge, 2002; Malhotra and 
Kaufman, 2007).  The PERK pathway impedes protein translation and synthesis, and 
converges with the ATF6 pathway to up-regulate a number of chaperone proteins, as well 
as induce apoptosis (Teske et al., 2011). 
The UPR occurs in a number of normal processes including plasma cell differentiation 
(Iwakoshi et al., 2003), muscle development (Nakanishi et al., 2005) and keratinocyte 
differentiation (Sugiura et al., 2009).  In contrast, the UPR has also been implicated in a 
number of diseases including Alzheimer‟s disease (Imaizumi et al., 2001), Huntington‟s 
disease (Vidal et al., 2012), atherosclerosis (Zhou et al., 2005) and diabetes (Scheuner 
and Kaufman, 2008) to name a few.  The UPR is also involved in normal lens 
development, however, autosomal dominant Cx50 mutants (G22R and S59P) that result 
in cataracts are retained in the ER and elevate the expression of UPR markers (Alapure et 
al., 2012).  In addition, autosomal dominant (G12R, G12D, R42P, C86S and F137L) (Di 
et al., 2002; He et al., 2005) and recessive (L34P) (Gottfried et al., 2002) Cx31 mutants 
linked to EKV, exhibited trafficking defects that could manifest as an UPR.  In fact, 
while all autosomal dominant Cx31 mutants induced cell death (Di et al., 2002; He et al., 
2005), some were indeed reported to induce an ER stress-mediated UPR (Tattersall et al., 
2009). 
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1.14 Hypothesis 
We hypothesized that Cx30 mutations result in various skin diseases and non-syndromic 
hearing loss through several distinct mechanisms.  To test this hypothesis, we 
characterized four Cx30 mutants (T5M, V37E, G59R and A88V) in connexin-deficient 
HeLa cells and GJIC-competent REKs, and examined the ability of each mutant to form 
functional gap junction channels and hemichannels at the cell surface.  In addition, Cx30 
mutants were assessed for their ability to induce cell death and evoke an unfolded protein 
response.  Finally, trafficking-defective Cx30 mutants were co-expressed with wild-type 
Cx30 and Cx26 to determine if they could be rescued from intracellular compartments to 
the cell surface.  Cx30 mutants were also examined for their ability to out-compete co-
expressed wt Cx30 and Cx26, known as exhibiting dominant-negative and transdominant 
effects, respectively, causing the wt connexins to be retained inside the cell.  The overall 
goal of these studies was to determine the mechanisms underlying each disease-linked 
Cx30 mutant. 
1.15 Objectives 
The specific objectives of this study were to: 
 
1. Characterize the subcellular localization and function of T5M, V37E, G59R and 
A88V Cx30 mutants in REKs and HeLa cells. 
 
2. Determine the cell death mechanisms activated by V37E and A88V Cx30 
mutants. 
 
3. Examine the potential dominant-negative and transdominant effects of Cx30 
mutants on co-expressed wild-type Cx30 and Cx26. 
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Chapter 2  
2 Skin diseases and non-syndromic hearing loss linked to 
Cx30 mutations arise through several distinct 
mechanisms 
Connexin 30 (Cx30), a member of the large gap junction protein family, plays a role in 
the homeostasis of the epidermis and inner ear through gap junctional intercellular 
communication (GJIC).  Here, we investigated the underlying mechanisms of four 
autosomal dominant Cx30 gene mutations linked to hearing loss and/or various skin 
diseases.  First, the T5M mutant linked to non-syndromic hearing loss formed functional 
gap junction channels and hemichannels, similar to wild-type Cx30.  The loss-of-function 
V37E mutant associated with keratitis-ichthyosis-deafness (KID) syndrome was retained 
in the endoplasmic reticulum and significantly induced unfolded protein response (UPR)-
mediated apoptosis.  The G59R mutant linked to Vohwinkel and Bart-Pumphrey 
syndromes was retained primarily in the Golgi apparatus and exhibited loss of gap 
junction channel and hemichannel function.  Lastly, the A88V mutant related to Clouston 
syndrome also significantly induced apoptosis, primarily through an UPR-independent 
mechanism.  Collectively, we discovered that four unique Cx30 mutants cause disease 
through different mechanisms that likely include their selective dominant-negative and 
transdominant effects on co-expressed connexins, highlighting the overall complexity of 
connexin-linked diseases and the importance of GJIC in disease prevention.   
 
 
 
 
A version of this chapter has been submitted to the Journal of Cell Science: 
Berger, A.C., Shao, Q., and Laird, D.W.  Skin diseases and non-syndromic hearing loss 
linked to Cx30 mutations arise through several distinct mechanisms. 
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2.1 Introduction 
Gap junctions are clusters of specialized intercellular channels that regulate the direct 
exchange of ions and various hydrophilic cellular metabolites smaller than 1000 Da, a 
process known as gap junctional intercellular communication (GJIC) (Alexander and 
Goldberg, 2003).  Two inter-docked connexons (hemichannels), one from each of two 
apposing cells, form a functional gap junction channel.  Each connexon is composed of 
six oligomerized connexin (Cx) subunits, and to date, the connexin family consists of 21 
members in humans (Sohl and Willecke, 2003; Sohl and Willecke, 2004).  Interestingly, 
while the primary function of gap junction channels is to facilitate intercellular 
communication, hemichannels have also been reported to exist and function at the cell 
surface in an undocked state, permitting the transfer of molecules between extracellular 
and intracellular environments (Anselmi et al., 2008; Burra and Jiang, 2011; Tong et al., 
2007).  Hemichannels formed from single or multiple types of connexins are termed 
homomeric and heteromeric, respectively, and gap junction channels are characterized as 
homotypic or heterotypic according to whether their channels are composed of the same 
or different connexons (Burra and Jiang, 2011).  Channel composition depends on the 
connexin expression profile of each cell and tissue type, as well as the natural 
compatibility of the connexins to intermix (Beyer et al., 2001; Burra and Jiang, 2011; 
Laird, 2006).   
Connexins are highly expressed in virtually all tissues in the human body, and GJIC plays 
an essential role in the regulation of cellular and physiological processes including 
proliferation, differentiation, apoptosis, growth and development (Alexander and 
Goldberg, 2003; Choudhry et al., 1997; Decrock et al., 2009; Kumar and Gilula, 1996; 
McLachlan et al., 2007).  In the inner ear and the skin, proper connexin expression and 
function directly relate to the maintenance of cochlear homeostasis and epidermal 
differentiation, respectively (Langlois et al., 2007; Wangemann, 2006; Zhao et al., 2006).  
In the cochlea, Cx26, Cx29, Cx30, Cx31 and Cx43, found in the epithelial and connective 
tissue gap junction networks, play a crucial role in sound transduction.  Cx26, and 
possibly other connexins, are thought to be involved in the recycling of K
+
 through the 
supporting cells back to the endolymphatic space, for potential re-entry into sensory cells 
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when activated by an acoustic stimulus (Kikuchi et al., 2000; Nickel and Forge, 2008).  
Interestingly, at least seven connexins, including Cx26, Cx30 and Cx43, are temporally 
and spatially expressed at the protein level in the human epidermis with overlapping 
distribution in the various non-cornified epidermal strata (Di et al., 2001; Kretz et al., 
2004).  While GJIC plays an important role in epidermal differentiation, it is also critical 
to the wound healing process (Churko and Laird, 2013; Langlois et al., 2007).  Here we 
focus on Cx30, which in humans, is predominantly expressed in the inner ear and 
epidermis (Di et al., 2001; Nickel and Forge, 2008). 
Connexin mutations have been linked to a number of different diseases ranging from 
developmental disorders to congenital cataracts (Laird, 2006).  Mutations in the genes 
encoding Cx26, Cx30, Cx30.3 and Cx31 in particular have been linked predominantly to 
hearing loss and various skin diseases (Di et al., 2001).  Importantly, mutations in Cx30 
and Cx26, the most predominant connexins in the inner ear (Hoang Dinh et al., 2009), are 
the leading cause of nearly half the cases of inherited prelingual non-syndromic hearing 
loss (Chang et al., 2009; Schutz et al., 2010; Wang et al., 2011).   In particular, seven 
distinct single amino acid substitutions in the 1st half of the coding sequence of Cx30 are 
responsible for hearing loss and/or skin disease.  The T5M and A40V mutations have 
been linked to non-syndromic hearing loss, as no other tissues or organs where Cx30 is 
expressed were affected (Grifa et al., 1999; Wang et al., 2011).  Interestingly, hidrotic 
ectodermal dysplasia (HED), commonly known as Clouston syndrome, is a skin disease 
distinctly linked to G11R (Chen et al., 2010; Common et al., 2002; Zhang et al., 2003), 
V37E (Common et al., 2002; Jan et al., 2004; Smith et al., 2002), D50N (Baris et al., 
2008) and A88V (Common et al., 2002; Essenfelder et al., 2004) Cx30 mutations.  This 
rare disease has a founder effect within the French-Canadian population and is 
characterized by palmoplantar hyperkeratosis (PPK), nail dystrophies, and partial to 
complete alopecia (Kibar et al., 2000; Zhang et al., 2003).  In some patients, other 
symptoms like ocular and craniofacial abnormalities, hearing loss and abnormal sweating 
and cardiac findings have been reported (Christianson and Fourie, 1996; Fraser and Der 
Kaloustian, 2001; Lamartine et al., 2000).  Interestingly, one patient harbouring a V37E 
Cx30 mutation was diagnosed with keratitis-ichthyosis-deafness (KID) syndrome, which 
is commonly associated with Cx26 mutations.  This patient experienced Clouston 
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syndrome-like symptoms, but also hearing impairment and vascularising keratitis (Jan et 
al., 2004).  Finally, a G59R Cx30 mutation results in the development of classical 
Vohwinkel syndrome and Bart-Pumphrey syndrome (Nemoto-Hasebe et al., 2009), which 
are also diseases most commonly caused by mutations in Cx26 (Bakirtzis et al., 2003; Jan 
et al., 2004; Richard et al., 2004).  Both syndromes result in PPK and sensorineural 
hearing loss, however, Bart-Pumphrey syndrome can be distinguished by the formation 
of knuckle pads, while patients with Vohwinkel syndrome develop constriction bands 
that cause spontaneous auto-amputation of the digits (pseudoainhum) (Bakirtzis et al., 
2003; Richard et al., 2004). 
Previously, studies on a few of the Cx30 disease-linked mutations have revealed reduced 
or abolished gap junction function, as the majority of mutant proteins are retained in 
subcellular compartments (Common et al., 2002; Essenfelder et al., 2004; Wang et al., 
2011).  Typically, most connexins follow the traditional secretory pathway by folding in 
the endoplasmic reticulum (ER), oligomerizing into connexons either in the ER or Golgi 
apparatus and by employing microtubules for efficient trafficking to the plasma 
membrane (Laird, 2006).  Disruptions to any stage of this connexin transport process can 
have detrimental cellular effects and commonly result in connexin-linked diseases (Laird, 
2006).  In particular, ER stress can result from the accumulation of misfolded proteins in 
the ER, which has been reported to trigger a process known as the unfolded protein 
response (UPR) (Malhotra and Kaufman, 2007).  Typically, quality control mechanisms 
involving chaperones in the ER facilitate the re-folding of misfolded proteins for export 
out of the ER (Groenendyk and Michalak, 2005).  The UPR involves the activation of 
three ER membrane-bound sensors that work collectively to attenuate mRNA translation 
and protein synthesis, increase the folding capacity of the ER through the up-regulation 
of chaperone proteins, increase lipid synthesis and force misfolded proteins through an 
ER-associated degradation (ERAD) pathway to relieve ER stress and maintain cellular 
homeostasis (Malhotra and Kaufman, 2007).  Failure of these processes to reduce ER 
stress results in the induction of apoptosis (Groenendyk and Michalak, 2005; Rasheva 
and Domingos, 2009). 
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Currently, it is poorly understood how Cx30 mutations manifest into syndromic and non-
syndromic diseases involving the skin and cochlea.  In the present study, we 
characterized four different Cx30 mutants linked to non-syndromic hearing loss, 
Clouston syndrome, KID syndrome and Vohwinkel/Bart-Pumphrey syndromes to gain 
critical insight into the mechanisms behind these distinct disease manifestations.  Our 
results indicate that the T5M mutant associated only with non-syndromic hearing loss 
formed functional gap junction channels, while the skin disease-linked mutants were 
primarily retained in intracellular compartments, reducing channel function.  In addition, 
since we showed that the V37E and A88V mutants, linked to KID syndrome and/or 
Clouston syndrome, induced cell death in keratinocytes, we investigated the potential 
mechanisms of cell death and discovered that both mutants induced apoptosis.  In 
particular, we propose that the V37E mutant evoked an UPR which drove cells into 
apoptosis, while the A88V mutant may exert its effects through a different mechanism.  
Finally, we demonstrated that skin disease-linked mutants are not rescued by co-
expressed wild-type (wt) Cx30 or Cx26 in rat epidermal keratinocytes (REKs), and in 
particular, the V37E and A88V mutants may have a dominant-negative effect on these 
co-expressed connexins.  Collectively, these studies demonstrate the complexity of the 
mechanisms involved in connexin-linked diseases, as the T5M Cx30 mutant exhibited 
intercellular channel and hemichannel function, yet still causes disease.  Additionally, the 
V37E mutant highlights Cx30 mutant-driven UPR and apoptosis as a previously 
unreported mechanism of how Cx30 mutations may cause disease. 
2.2 Materials and Methods 
2.2.1 Generation of cDNA constructs 
Mouse Cx30 complementary DNA (cDNA) encoded within the pBluescript vector, 
kindly provided by Dr. C. C. Naus (UBC, Vancouver, BC), was digested with XhoI and 
NotI to remove the green fluorescent protein (GFP) cDNA sequence as described by 
Thomas et al. (2004).  Cx30 mutants were constructed using the QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA) as per the manufacturer‟s instructions.  
The following primer pairs were used to create the Cx30 mutations.  The nucleotide 
change is underlined in each case:  
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T5M: sense, 5‟-GCACGATGGACTGGGGGATGCTGCACACCGTCATCGG-3‟; 
antisense, 5‟-CCGATGACGGTGTGCAGCATCCCCCAGTCCATCGTGC-3‟;  
V37E: sense, 5‟-CCGAGTCATGATCCTAGAGGTGGCTGCCCAG-3‟; antisense, 5‟-
CTGGGCAGCCACCTCTAGGATCATGACTCGG-3‟;  
A88V: sense, 5‟-CTTTGTGTCTACCCCAGTCCTGTTGGTGGCCATGC-3‟; antisense, 
5‟-GCATGGCCACCAACAGGACTGGGGTAGACACAAAG-3‟.   
The G59R mutant was purchased from Norclone Biotech Laboratories (London, ON).  
All mutations were validated by sequencing, indicating the presence of the mutation and 
ensuring that no other mutations were introduced.   
To create GFP-tagged constructs and red fluorescent protein (RFP)-tagged Cx30 (Cx30-
RFP), polymerase chain reaction (PCR) was performed to introduce XhoI and EcoRI 
restriction sites to the 5‟ and 3‟ ends of the Cx30 and Cx30 mutant sequences, 
respectively, effectively removing the stop codon.  Following digestion with XhoI and 
EcoRI restriction enzymes, the PCR products were cloned into the pEGFP-N1 (Clontech, 
Palo Alto, CA) and pTagRFP-N (Cedarlane, Burlington, ON) vectors to produce GFP-
tagged constructs and Cx30-RFP, respectively.  All constructs were sequenced for 
verification. 
2.2.2 Cell culture and transient transfections 
GJIC-competent REKs, kindly provided by Dr. Vincent C. Hascall (Cleveland Clinic, 
Cleveland, OH) and connexin-deficient HeLa cells (ATCC, Manassas, VA) were cultured 
in high glucose Dulbecco‟s modified Eagle‟s medium (DMEM) supplemented with 10% 
fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin and 2 mM L-
glutamine (Invitrogen, Burlington, ON), in a humidified incubator maintained at 37°C 
with 5% CO2 as previously described (Maher et al., 2005).  Cells were passed once they 
reached 80-100% confluency using 0.25% trypsin-ethylene-diamine-tetraacetic acid 
(trypsin-EDTA) (Invitrogen), and were cultured in 35 mm or 60 mm plastic tissue culture 
dishes for all experimental procedures.  Prior to transfection, all cells were grown to 65-
80% confluency, and those destined for immunolabeling or cell death assays were also 
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grown on glass coverslips.  Cells were transfected with 2-6 µg of DNA using 
Lipofectamine 2000 (Invitrogen) in the presence of low serum optimal minimal essential 
medium (Opti-MEM) (Invitrogen) as previously described (Penuela et al., 2007), or using 
the Polyplus JetPRIME-mediated transfection kit (VWR International, Mississauga, ON) 
according to the manufacturer‟s instructions.  As controls, cells were exposed to 
transfection reagents and the appropriate media without the addition of any DNA, and are 
referred to in the following experiments and figures as wt.  As a second control, a 
population of cells was also transfected with a vector encoding free GFP.  Co-
transfections were performed using the Polyplus JetPRIME transfection method by 
mixing 1µg of Cx30- or Cx26-RFP and 1 µg of each GFP-tagged Cx30 mutant.  All 
transfections were terminated after 24 hours.  Positive controls for the induction of ER 
stress or apoptosis included cells plated in parallel, treated for 24 hours with 2 µg/mL 
tunicamycin (Tm) or 0.5 µg/mL staurosporine (Stauro), respectively (both from Sigma 
Aldrich, St Louis, MO). 
2.2.3 Immunolabelling 
Cells grown in monolayer on glass coverslips were fixed with 10% neutral buffered 
formalin (NBF) (EMD Millipore, Billerica, MA) for 25 minutes at room temperature.  In 
a humidified chamber, fixed cells were blocked for 30-45 minutes at room temperature in 
phosphate buffered saline (PBS) containing 2% bovine serum albumin (BSA) (Santa 
Cruz Biotechnology, Dallas, TX) to prevent non-specific antibody binding and 0.1% 
Triton X-100 (Sigma Aldrich) for permeabilization.  Endogenous or ectopic connexin 
expression and localization was detected by labeling with rabbit anti-Cx43 (1:400, Sigma 
Aldrich) or anti-Cx30 (1:500, Invitrogen) antibodies for 1 hour. In some cases, cells were 
labeled with mouse anti-protein disulfide isomerase (PDI) (1:500, Enzo Life Sciences, 
Farmingdale, NY) to denote the position of the ER, mouse anti-Golgi matrix protein 130 
(GM130) (1:500, BD Transduction Laboratories, Mississauga, ON) to demarcate the 
Golgi apparatus or rabbit anti-cleaved caspase-3 (1:1000, Cell Signaling Technology, 
Danvers, MA) to denote cells undergoing apoptosis.  Cells were then incubated with 
secondary AlexaFluor555 or AlexaFluor488 conjugated antibodies (1:500, Invitrogen) 
for 45-60 minutes, and stained for 5-10 minutes with Hoescht 33342 (1:1000, Invitrogen) 
40 
 
to denote the nuclei.  Cells were mounted on glass microscope slides with Airvol 
mounting medium.  Cells co-transfected with Cx30- or Cx26-RFP and GFP-tagged Cx30 
mutants were not immunolabeled, but were stained with Hoescht 33342 and mounted as 
described above.  All slides were stored at 4°C with minimal exposure to light.  Slides 
were imaged using a Zeiss LSM 410 confocal microscope (Thornwood, NY) equipped 
with a 63X lens as previously outlined by Thomas et al. (2007). 
2.2.4 Microinjection assays 
In order to test Cx30 and mutant gap junction function, REKs and HeLa cells ectopically 
expressing Cx30 or mutants were microinjected with 10 mM Alexa Fluor 350 hydrazide 
(Invitrogen) using an automated Eppendorf FemtoJet microinjection system 
(Mississauga, ON), as previously described (Huang et al., 2013).  For each biological 
replicate of GFP-, Cx30-, T5M-, V37E- and G59R-expressing cells, ~15-20 cells were 
microinjected and the incidence of dye transfer to surrounding cells was recorded.  
Images were acquired using a Leica DM IRE2 inverted epifluorescent microscope 
(Richmond Hill, ON), equipped with a Hamamatsu digital camera (Bridgewater, NJ) and 
OpenLab 5.5.3 Imaging Software (Lexington, MA).  HeLa cells expressing the A88V 
mutant could not be microinjected due to the fact that cells were already undergoing cell 
death and had a permeable cell membrane, however in the case of REKs, 5-10 cells were 
microinjected in each replicate.  REKs and HeLa cells were microinjected and processed 
in the same manner to ensure that cells were well coupled and connexin-deficient, 
respectively.  A one-way analysis of variance statistical test (ANOVA) and Tukey‟s post 
hoc test were performed on the averages of 3 biological replicates (N=3), and values 
represent the mean percent incidence of dye transfer ± standard error of the mean (SEM). 
2.2.5 Dye uptake hemichannel assays 
To assess Cx30 and mutant hemichannel function, dye uptake assays were performed as 
previously described by Tong et al. (2007), with some modifications.  Briefly, HeLa cells 
plated at about 20-30% confluency as single isolated cells were transfected with 1.5 µg of 
DNA as described above using Lipofectamine 2000.  Regular extracellular solution 
(ECS) and divalent cation free-ECS (DCF-ECS) were made with 25 mM D-glucose, and 
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cells were incubated with 500 µL of solution containing 0.15 mM propidium iodide (PI) 
(Invitrogen).  Groups of single isolated Cx30- or mutant-expressing cells were analyzed 
for their ability to uptake PI under physiological (ECS) and no Ca
2+
 or Mg
2+
 (DCF-ECS) 
conditions.  Isolated GFP-positive cells were quantified in the assay, and neighbouring 
cells attached by a single long cytoplasmic projection were also included.  Approximately 
60 cells were recorded for each biological replicate.  Images were taken under a 20X lens 
using the Leica microscope and OpenLab software.  The number of cells that exhibited 
dye uptake was recorded as a percentage of the total number of GFP-positive cells 
examined, and a two-way ANOVA was performed on the averages of 4 biological 
replicates (N=4).  Values represent the mean percentage of GFP-positive isolated cells 
that exhibited dye uptake ± SEM.  
2.2.6 TUNEL assays 
Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assays were 
performed using an ApopTag® Red In Situ Apoptosis Detection Kit (EMD Millipore) as 
per the manufacturer‟s instructions, with a few modifications.  Briefly, control and 
mutant-expressing cells grown in monolayer were fixed in 10% NBF, permeabilized for 
10 minutes with 0.5% Triton X-100 in PBS, and subsequently washed with 1X PBS.  
Following the incubation period with terminal deoxynucleotidyl transferase (TdT) 
enzyme at 37°C, cells were washed with working strength Stop/Wash buffer twice for 5 
minutes each wash.  Nuclei were stained with Hoescht 33342 and mounted.  Images were 
obtained using the Leica microscope and OpenLab Software with a 63X oil immersion 
objective lens.  For each biological replicate of transfected cells and controls, 10-15 
images were taken of random areas.  The number of ApopTag positive cells was recorded 
as a percentage of the total cell number per image and a one-way ANOVA and Tukey‟s 
post hoc test were performed on the averages of 3 biological replicates (N=3).  Values 
represent the mean percentage of apoptotic cells/total number of cells per image ± SEM. 
2.2.7 Western blotting 
Cell lysates were collected from cultures using a Triton-based extraction buffer [1% 
Triton X-100 (Sigma Aldrich), 150 mM NaCl, 10 mM Tris, 1 mM EDTA, 1 mM 
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ethylene glycol tetraacetic acid (EGTA), 0.5% nonyl phenoxypolyethoxylethanol (NP-
40), 100 mM NaF, 100 mM sodium orthovanadate and one proteinase inhibitor mini-
EDTA tablet (Roche Applied Science, Laval, QC)] adjusted to pH 7.4 as previously 
described by (Stewart et al., 2013).  Extractions were repeated 3 times, and protein lysate 
concentrations were quantified using a bicinchoninic acid (BCA) protein determination 
kit (Thermo Scientific, Rockford, IL).  Total protein lysates of 50 µg were resolved by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 10% 
polyacrylamide gels and transferred to nitrocellulose membranes using the iBlot Dry 
Blotting System (Invitrogen).  Membranes were blocked using 5% Blotto Non-Fat Dry 
Milk (Santa Cruz Biotechnology) with 0.05% Tween 20 (Sigma Aldrich) in PBS (PBS-T) 
for 30-60 minutes, and subsequently incubated overnight at 4°C with rabbit anti-Cx30 
(1:750-1000, Invitrogen), rabbit anti-Cx43 (1:5000, Sigma Aldrich), goat anti-glucose 
regulated protein 78 (GRP78) (1:500, Santa Cruz Biotechnology), mouse anti-C/EBP 
homologous protein (CHOP) (3 µg/mL, Abcam, Toronto, ON) and mouse anti-activating 
transcription factor 4 (ATF4) (5 µg/mL, Abcam) primary antibodies.  Gel loading 
controls included probing for the levels of β-tubulin using mouse anti-β-tubulin primary 
antibody (1:10000, Sigma Aldrich).  Blots probed for Cx30 were counterstained with 
mouse anti-GFP antibodies (1:2500, EMD Millipore) to validate that the GFP tag was 
attached to Cx30 and Cx30 mutants.  After several washes with PBS-T, blots were then 
incubated with secondary anti-rabbit and anti-goat Alexa Fluor 680 (1:5000, Invitrogen) 
and anti-mouse IRdye 800 (1:5000, LI-COR Biosciences, Lincoln, NE) secondary 
antibodies for 45-60 minutes.  Following more PBS-T washes, blots were scanned and 
densitometry measurements were quantified using the Odyssey Infrared Imaging System 
(LI-COR Biosciences).  Each signal was normalized to its β-tubulin loading control in the 
same lane, and the wt/β-tubulin or Cx30/β-tubulin outcome value was set to 1.  Unpaired 
t-tests were performed on the fold change averages of these values from 3 distinct sets of 
protein lysates to minimize variation between blots as well as between mutant lysates 
within each blot.  Values represent fold change ± SEM. 
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2.3 Results 
2.3.1 Cx30 mutations linked to skin disease and non-syndromic 
hearing loss, and their differential ectopic expression and 
localization in REKs 
Cx30 is a 261 amino acid gap junction protein that exhibits the topological structure of a 
typical connexin, with four transmembrane domains, two extracellular loops, one 
intracellular loop and cytoplasmic-exposed amino and carboxy termini (Fig. 2.1A).  The 
location of four distinct mutations that cause skin disease and/or hearing loss are all 
located within the 1st half of the Cx30 protein (Fig. 2.1A). 
Western blot analysis was used to determine the expression levels of GFP-tagged T5M, 
V37E, G59R and A88V mutants in REKs.  Quantification of densitometry values 
revealed that V37E-GFP and A88V-GFP protein levels were ~35% and ~50% lower, 
respectively, compared to the relative expression of Cx30-GFP (P<0.01) (Fig. 2.1B, C).  
In contrast, the non-syndromic hearing loss-linked T5M and Vohwinkel syndrome-linked 
G59R mutants exhibited expression levels similar to that of Cx30-GFP. 
To compare the localization profiles of the mutant forms of Cx30, we examined GFP-
tagged Cx30 mutants (Fig. 2.2A) and untagged Cx30 mutants (Fig. 2.2B, C) in REKs.  
Consistent with previous reports, the T5M mutant formed gap junction-like plaques at the 
cell surface similar to wt Cx30 (Common et al., 2002), while the V37E and A88V 
Clouston syndrome-linked mutants remained in intracellular compartments (Common et 
al., 2002; Essenfelder et al., 2004) (Fig. 2.2A, B).  Immunolabeling for ER-resident 
chaperone PDI revealed that the Clouston syndrome/KID syndrome-linked V37E mutant 
was retained in the ER (Fig. 2.2A).  A88V mutant-expressing cells appeared to be 
entering a cell death pathway as they exhibited small fragmented nuclei, and since they 
lacked PDI staining, it remains unclear whether a population of this mutant resided in the 
ER.  The novel Vohwinkel syndrome-linked G59R mutant (Nemoto-Hasebe et al., 2009) 
also showed an intracellular localization profile (Fig. 2.2A, B), and immunolabeling for 
GM130 revealed its localization largely in the Golgi apparatus (Fig. 2.2C).  Interestingly, 
while we have never observed V37E plaques at the interface between apposing cells, a 
population of the G59R and A88V mutants successfully trafficked to the cell surface 
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Figure 2.1: Cx30 mutations linked to hearing loss and skin diseases, and their 
differential ectopic expression in REKs   
(A) Schematic diagram of Cx30 depicting four mutations associated with hearing loss 
(yellow), hearing loss plus skin disease (orange) and skin disease (green).  (B) Western 
blot analysis was used to detect the levels of GFP-tagged Cx30 and Cx30 mutants when 
ectopically expressed in REKs.  Blots were probed with anti-Cx30, anti-GFP or anti--
tubulin antibodies.  (C) Anti-GFP labeling revealed significantly lower levels of GFP-
tagged V37E and A88V mutants compared to the levels of wild-type Cx30.  Values 
represent fold change ± SEM (unpaired t-test, **P<0.01, N=3). 
 
 
46 
 
 
47 
 
Figure 2.2:  Skin disease-linked Cx30 mutants have impaired abilities to form gap 
junction plaques.  (A) Wild-type (wt) REKs and REKs ectopically expressing GFP-
tagged Cx30 or Cx30 mutants (green) were immunolabeled for protein disulfide 
isomerase (PDI) (red) to denote the endoplasmic reticulum (ER).  Nuclei were stained 
with Hoescht 33342 (blue).  Cx30 and the T5M mutant formed punctate gap junction-like 
structures at the cell-to-cell interface, while V37E co-localized with PDI.  The G59R and 
A88V mutants were primarily localized in intracellular compartments, however a 
population of the mutants did reside at the cell surface (white arrows).  PDI staining was 
absent in A88V mutant-expressing cells, and GFP-positive cells without nuclei 
represented dead “ghost” cells.  Scale bar = 20µm.  (B) Immunolabeling REKs for Cx30 
(green) revealed that untagged mutants exhibited similar localization profiles as GFP-
tagged mutants.  Similarly, populations of the G59R and A88V mutants localized to the 
cell surface (arrows).  Scale bar = 20µm.  (C) REKs ectopically expressing the G59R 
mutant were double-labeled for Cx30 (green) and Golgi matrix protein 130 (GM130) 
(red), which revealed that the G59R mutant co-localized with the Golgi apparatus.  Scale 
bar = 20µm.   
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(Fig. 2.2A, B, arrows).  Cx30 and Cx30 mutants all similarly localized within the cell 
regardless of the presence or absence of the GFP tag (Fig. 2.2A-C). 
2.3.2 V37E and G59R skin disease-linked mutants exhibit loss of 
gap junction function 
Since the T5M mutant and a population of the G59R mutant formed punctate gap 
junction-like structures at the cell surface in REKs, we hypothesized that these mutants 
may form functional gap junctions.  Mutant-expressing GJIC-deficient HeLa cells were 
microinjected with Alexa 350 to assess whether any of the mutants restored GJIC.  As 
expected, Cx30 gap junction channels readily facilitated dye transfer (P<0.001), while wt 
and free GFP-expressing cells showed no significant dye transfer to surrounding cells 
(Fig. 2.3A, B).  Interestingly, the T5M mutant exhibited dye transfer in ~90% (P<0.001) 
of cells injected (Fig. 2.3A, B), indicating that this mutant was functional.  No dye 
transfer was observed in microinjected HeLa cells expressing the V37E and G59R 
mutants (Fig. 2.3A).  A88V-expressing cells were not included in these functional 
studies, as they could not be microinjected due to their porous cell membranes caused by 
cell death (data not shown). 
Next, we assessed the ability of each Cx30 mutant to form functional hemichannels by 
observing the incidence of PI dye uptake in cells under normal ECS  and no Ca
2+
 or Mg
2+
 
DCF-ECS conditions, the latter of which induces hemichannels to open (Lai et al., 2006; 
Stout et al., 2002). Under ECS conditions, Cx30 and T5M, V37E and G59R mutant 
hemichannels remained closed as expected, indicating that the mutants did not exhibit 
leaky or abnormal activity (Fig. 2.4A).  Under DCF-ECS conditions, ~90% of single 
isolated T5M-expressing cells exhibited dye uptake, closely resembling the ~95% 
incidence observed for cells expressing Cx30, both of which were significantly higher 
than that observed under control ECS conditions (P<0.001) (Fig. 2.4A, B). Collectively, 
these functional studies indicated that V37E and G59R mutants were loss-of-function 
mutants while the T5M mutant showed similar functional channel properties to Cx30.   
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Figure 2.3:  Skin disease-linked V37E and G59R mutants exhibit loss of gap 
junction function when ectopically expressed in HeLa cells 
(A) Free GFP-, Cx30-GFP- and mutant-GFP-expressing HeLa cells (denoted in phase-
contrast images) were imaged for the presence of GFP and microinjected with Alexa 350 
dye (red asterisks).  Scale bar = 20µm.  (B) Relative to wild-type (wt) control cells, cells 
expressing Cx30 or the T5M mutant exhibited significantly greater incidences of dye 
transfer than those expressing the V37E or G59R mutants.  Values represent the mean 
percent incidence of dye transfer ± SEM (one-way ANOVA, ***P<0.001, N=3).  Total 
numbers of injected cells are presented along the bottom of the figure. 
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Figure 2.4:  The hearing loss-linked T5M mutant exhibits hemichannel activity in 
HeLa cells that mimics Cx30 
(A) Single isolated Cx30-GFP- or mutant-GFP-expressing HeLa cells (denoted in phase-
contrast images) were incubated with propidium iodide (PI) in normal extracellular 
solution (ECS) or divalent cation free ECS (DCF-ECS).  Cells were imaged for the 
presence of GFP (green) and PI uptake (red).  Scale bar = 20µm.  (B) Cells expressing the 
V37E and G59R mutants did not exhibit PI uptake under DCF-ECS conditions, while 
those expressing Cx30 or the T5M mutant exhibited significant hemichannel activity.  
Values represent the mean percentage of GFP-positive isolated cells that exhibited PI 
uptake ± SEM (two-way ANOVA, ***P<0.001, N=4).   
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2.3.3 V37E and A88V mutants reduce Cx43-based coupling in 
REKs by potentially affecting Cx43 plaque formation 
In Cx43-rich REKs engineered to express GFP-tagged Cx30 or the T5M and G59R 
mutants, Cx43 was frequently co-localized with Cx30 mutants at cell-to-cell interfaces.  
Cx43-based gap junctions appeared less frequently between cells expressing the V37E 
and A88V mutants (Fig. 2.5A), however the total protein levels of Cx43 remained 
unchanged (Fig. 2.5B, C).  Total Cx43 levels were only slightly decreased in T5M 
mutant-expressing cells compared to those expressing Cx30 (P<0.05).   
To determine whether Cx30 mutants affected Cx43-based GJIC, REKs were 
microinjected with Alexa 350 and the incidence of dye transfer was recorded.  Wt REKs 
exhibited 100% dye transfer, and no significant differences were observed in REKs 
expressing free GFP, Cx30-GFP, or the GFP-tagged T5M and G59R mutants.  Cell pairs 
or clusters expressing the V37E and A88V mutants exhibited decreased Cx43-mediated 
dye transfer (P<0.01) (Fig. 2.6A, B). 
2.3.4 V37E and A88V mutants induce apoptosis 
The ectopic expression of the V37E and A88V mutants induced some degree of cell 
death in REKs as early as 18 hours post-expression with the majority of A88V-
expressing cells dying within 48 hours (data not shown).  To determine the mechanism of 
cell death induced by these mutants, control and mutant-expressing REKs were 
immunolabeled with anti-cleaved caspase-3, a marker of the committed stage of 
apoptosis (Saraste and Pulkki, 2000).  Interestingly, some V37E- and A88V-expressing 
REKs expressed cleaved caspase-3, indicating that these cells were undergoing apoptosis 
(Fig. 2.7).  To further validate this finding, TUNEL assays representing the degradation 
stage of apoptosis (Saraste and Pulkki, 2000) were performed on Cx30- and mutant-
expressing REKs.  V37E and A88V Cx30 mutants significantly induced apoptosis, as 
~30% and ~35% of total cells respectively were ApopTag positive (P<0.001) compared 
to wt REKs of which ~2% were ApopTag positive (Fig. 2.8A, B).  Cells treated for 24 
hours with staurosporine, a strong protein kinase inhibitor (Chae et al., 2000), served as  
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Figure 2.5:  Skin disease-linked V37E and A88V mutants may reduce Cx43 plaque 
formation in REKs, although total levels of Cx43 remain unchanged 
(A) Cx30-GFP- and Cx30 mutant-GFP-expressing REKs (green) were immunolabeled 
for Cx43 (red) and stained with Hoescht 33342 (blue) to denote cell nuclei.  Cx43 
plaques were localized at the cell surface between REKs expressing Cx30 or the T5M 
and G59R mutants.  V37E- and A88V-expressing REKs did not exhibit Cx43 plaque 
formation between apposing cells.  Scale bar = 20µm.  (B) Western blot analysis was 
used to detect total levels of Cx43 in Cx30- and mutant-expressing cells when normalized 
to -tubulin.  (C) Total levels of Cx43 were slightly lower in REKs expressing only the 
T5M hearing loss-linked mutant and remained unchanged in V37E, G59R and A88V 
mutant-expressing cells.  Values represent fold change ± SEM (unpaired t-test, *P<0.05, 
N=3). 
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Figure 2.6:  V37E and A88V skin disease-linked mutants reduce Cx43-based gap 
junction coupling in REKs.   
(A) Wild-type (wt) and free GFP-, Cx30-GFP- and mutant-GFP-expressing REKs 
(denoted by phase-contrast images) were imaged for the presence of GFP and 
microinjected with Alexa 350 dye (red asterisks).  Scale bar = 20µm.  (B) Relative to wt 
controls, cells expressing the V37E and A88V mutants exhibited significantly lower 
incidences of Cx43-mediated dye transfer.  Values represent the mean percent incidence 
of dye transfer ± SEM (one-way ANOVA, **P<0.01, N=3).  Total numbers of injected 
cells are presented along the bottom of the figure. 
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Figure 2.7:  REKs expressing V37E and A88V mutants express cleaved caspase-3.  
Wild-type (wt) or free GFP-, Cx30-GFP- and mutant-GFP-expressing REKs (green) were 
immunolabeled for cleaved caspase-3 (red) and nuclei were stained with Hoescht 33342 
(blue).  Cells expressing the V37E and A88V mutants also expressed the apoptotic 
marker cleaved caspase-3.  Scale bar = 20 µm. 
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Figure 2.8:  Ectopic expression of V37E and A88V mutants induces apoptosis in 
REKs.  (A) TUNEL assays were performed on wild-type (wt), free GFP-, Cx30-GFP- 
and mutant-GFP-expressing REKs (green).  Nuclei were stained with Hoescht 33342 
(blue) and apoptotic cells are indicated by ApopTag staining (red).  Staurosporine 
(Stauro) treatment served as an inducer of apoptosis.  Scale bar = 20 µm.  (B)  The 
expression of V37E and A88V mutants, as well as staurosporine treatment, significantly 
induced apoptosis in REKs compared to controls.  Values represent the mean percentage 
of apoptotic cells/total number of cells per image ± SEM (one way ANOVA, 
***P<0.001, N=3). 
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positive controls for the assay, as ~90% of total cells were apoptotic (P<0.001) (Fig.  
2.8A, B).   
To determine whether apoptosis was triggered by an ER stress-mediated UPR, Western 
blot analyses of REK cell lysates were performed to detect changes in the levels of 
markers involved in different stages and pathways of the UPR.  REKs treated with 
tunicamycin (Tm), an ER stress inducer that blocks N-glycosylation of proteins (de 
Freitas Junior et al., 2011), served as positive controls for UPR markers.  GRP78 
expression was significantly higher in cells expressing GFP, Cx30 and the G59R mutant 
(P<0.05), which revealed that a slight ER stress response was common to the transfection 
process and not specific to the presence of the Cx30 mutants (Fig. 2.9A).  ATF4 was 
mildly up-regulated in cells expressing GFP (P<0.05) and the A88V mutant (P<0.05), 
although most predominantly in cells expressing the V37E mutant (P<0.001) (Fig. 2.9B).  
As a control, cells treated with Tm exhibited significantly increased ATF4 protein levels 
(P<0.01) (Fig. 2.9B).  Finally, CHOP was significantly up-regulated in V37E mutant-
expressing cells (P<0.05) and in Tm-treated cells (P<0.01) (Fig. 2.9C). 
2.3.5 V37E and A88V mutants may exhibit dominant-negative and 
transdominant effects on wt Cx30 and Cx26 when co-
expressed in REKs 
To determine whether skin disease-linked Cx30 mutants that were localized to 
intracellular compartments could be rescued to the cell surface, REKs were engineered to 
express Cx30-RFP or Cx26-RFP simultaneously with GFP-tagged Cx30 mutants.  Alone, 
Cx30-RFP formed gap junctions (Fig. 2.10), which facilitated the transfer of Alexa 350 
in HeLa cells and REKs (data not shown).  Cx30-GFP and T5M-GFP showed distinct co-
localization with Cx30-RFP, with limited intracellular localization (Fig. 2.10).  Wt Cx30 
did not appear to rescue the V37E mutant to the cell surface (Fig. 2.10).  Although the 
G59R and A88V mutants showed some co-localization with wt Cx30 at the cell surface, 
the majority of these mutants were localized in intracellular compartments, indicating 
lack of a trafficking rescue (Fig. 2.10).  Notably, the V37E and A88V mutants may 
exhibit partial dominant-negative effects on wt Cx30, as a large population of Cx30-RFP 
was retained inside the cell as compared to situations where Cx30-RFP was expressed  
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Figure 2.9:  Assessment of the unfolded protein response in mutant-expressing 
REKs.  Western blot analysis was used to detect the levels of unfolded protein response 
(UPR) markers glucose regulated protein 78 (GRP78) (A), activating transcription factor 
4 (ATF4) (B) and C/EBP homologous protein (CHOP) (C) in wild-type (wt) and GFP-, 
Cx30- and mutant-expressing REKs when normalized to β-tubulin.  Normalized wild-
type (wt) values were set to 1.  Protein lysates from tunicamycin (Tm)-treated cells 
served as an inducer of the UPR.  Blots were also probed with anti-β-tubulin antibody.  
(A) GRP78 was elevated in cells expressing free GFP, Cx30 or the G59R mutant 
(*P<0.05), and was highly up-regulated in Tm-treated cells (***P<0.001).  (B) ATF4 
was up-regulated in free GFP- and A88V-expressing cells (*P<0.05), and more markedly 
elevated in V37E-expressing cells (***P<0.001) and Tm-treated controls (**P<0.01).  
(C) CHOP was significantly up-regulated in V37E-expressing and Tm-treated cells only 
(*P<0.05 and **P<0.01).  Values represent fold change ± SEM (unpaired t-test, N=3). 
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Figure 2.10:  V37E and A88V Cx30 mutants exhibit a dominant-negative effect on 
ectopically-expressed Cx30 in REKs.  REKs co-expressing Cx30-RFP (red) together 
with GFP-tagged Cx30, T5M, V37E, G59R or A88V mutants (green) were stained with 
Hoescht 33342 (blue) to denote the cell nuclei.  Cx30, the T5M mutant and populations 
of the G59R and A88V mutants distinctly co-localized with Cx30-RFP at the cell surface.  
Wild-type Cx30 failed to rescue mutant trafficking as the V37E, and the majority of the 
G59R and A88V mutants, were primarily localized to intracellular compartments.  V37E 
and A88V Cx30 mutants exhibited a dominant-negative effect on wild-type Cx30, as 
Cx30-RFP was retained inside the cell and particularly co-localized with the A88V 
mutant.  Scale bar = 20µm. 
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alone (Fig. 2.10).  In particular, the A88V mutant and wt Cx30 exhibited overlapping co-
localization in a distinct subcellular compartment.  We also observed similar results in 
HeLa cells, however, the V37E mutant exhibited some gap junction-like structures at the 
cell surface that co-localized with wt Cx30 (Fig. 2.11).  Alone, Cx26-RFP formed gap 
junctions in REKs (Fig. 2.12).  Cx30-GFP, T5M-GFP and G59R-GFP also showed 
distinct localization with Cx26-RFP in REKs, however the V37E, A88V and the majority 
of the G59R mutant remained in intracellular compartments, indicating that wt Cx26 did 
not rescue the trafficking of these mutants (Fig. 2.12).  However, the V37E and A88V 
mutants also may exhibit transdominant effects on Cx26, as the majority of Cx26-RFP 
was retained inside the cell compared to when Cx26-RFP was expressed alone (Fig. 
2.12). 
2.4 Discussion 
In the present study, we first determined that the T5M mutant linked to non-syndromic 
hearing loss exhibited similar properties to Cx30, as it formed functional gap junctions 
and hemichannels, while skin disease-linked mutants exhibited impaired gap junction 
formation and function.  In particular, the V37E mutant linked to KID syndrome was 
retained in the ER and triggered UPR-mediated apoptosis, as indicated by the up-
regulation of ATF4 and CHOP.  In contrast, the G59R mutant associated with Vohwinkel 
and Bart-Pumphrey syndromes was primarily retained in the Golgi apparatus, however, 
did not induce cell death.  The A88V mutant linked to Clouston syndrome remained 
primarily in intracellular compartments, triggered the up-regulation of ATF4 and 
significantly induced apoptosis, although primarily through a UPR-independent 
mechanism.  Finally, we determined that skin disease-linked mutants retained in 
intracellular compartments were not rescued to the cell surface by co-expressed Cx43, 
Cx30 or Cx26, and the V37E and A88V mutants exhibited dominant-negative and 
transdominant effects on the trafficking of these connexins to the cell surface.  Thus, we 
clearly demonstrated the overall complexity of connexin-linked diseases, as each disease-
linked Cx30 mutant causes disease via a different mechanism. 
In order to evaluate the link between Cx30 mutants and disease, we used spontaneously 
immortalized, newborn REKs, which have previously been reported to express messenger  
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Figure 2.11:  Cx30 may partially rescue the trafficking of V37E and A88V mutants 
in HeLa cells.  HeLa cells co-expressing Cx30-RFP (red) together with GFP-tagged 
Cx30, T5M, V37E, G59R or A88V mutants (green) were stained with Hoescht 33342 
(blue) to denote the cell nuclei.   Cx30, T5M and populations of the V37E, G59R and 
A88V mutants distinctly co-localized with Cx30-RFP at the cell surface, however all skin 
disease-linked mutants were primarily intracellularly localized.  Scale Bar = 20µm. 
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Figure 2.12:  V37E and A88V Cx30 mutants exhibit a dominant-negative effect on 
ectopically-expressed Cx26 in REKs.  REKs co-expressing Cx26-RFP (red) together 
with GFP-tagged Cx30, T5M, V37E, G59R or A88V mutants (green) were stained with 
Hoescht 33342 (blue) to denote the cell nuclei.  Cx30, the T5M mutant and a population 
of the G59R mutant distinctly co-localized with Cx26-RFP at the cell surface.  Wild-type 
Cx26 failed to rescue skin disease-linked mutant trafficking as the V37E, A88V and the 
majority of the G59R mutants were primarily localized to intracellular compartments.  
V37E and A88V Cx30 mutants exhibited a (trans)dominant-negative effect on wild-type 
Cx26, as Cx26-RFP was retained inside the cell and particularly co-localized with the 
A88V mutant.  Scale bar = 20µm. 
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RNA (mRNA) for 9 connexins, including Cx30 (Maher et al., 2005), and are 
phenotypically similar to basal keratinocytes given their ability to differentiate and 
stratify (Langlois et al., 2007; Maher et al., 2005; Thomas et al., 2007).  At the protein 
level, REKs abundantly express Cx43, and only express Cx26 upon differentiation 
(Maher et al., 2005). The fact that REKs did not express detectable levels of Cx30 
allowed us to express and track both GFP-tagged and untagged versions of Cx30 and 
mutants.  Similar localization profiles and function were observed for all GFP-tagged and 
untagged Cx30 and Cx30 mutants, strongly suggesting that the presence of GFP on the 
C-terminal tail did not affect the properties of Cx30, similar to what has been reported for 
Cx26 (Marziano et al., 2003) and Cx43 (Jordan et al., 1999).   
2.4.1 The non-syndromic hearing loss-linked T5M mutant 
The T5M mutant is one of only two Cx30 mutants linked specifically to non-syndromic 
hearing loss (Grifa et al., 1999; Wang et al., 2011).  Consistent with our results, the T5M 
mutant was previously found to form gap junctions (Common et al., 2002), however, its 
functional capacity was controversial.  In vitro electrophysiological studies previously 
showed that the T5M amino acid substitution drastically altered electrical coupling (Grifa 
et al., 1999), while other reports showed restrictions in the transjunctional molecules that 
can pass through T5M channels (Common et al., 2002; Schutz et al., 2010; Zhang et al., 
2005).  In our study, we demonstrated that both T5M-based hemichannels and gap 
junction channels were functional to the passage of sizable molecules (e.g. prodium 
iodide, Alexa 350), raising the question as to why this mutant causes hearing loss.   
The answer may be linked to subtle changes in the N-terminal domain of Cx30 where the 
„threonine‟ to „methionine‟ substitution occurs.  Cx30 shares 76% sequence homology 
with Cx26 (Grifa et al., 1999), and while the crystal structure of Cx30 has not yet been 
resolved, the crystal structure of Cx26 has elucidated that the amino terminal tail lines the 
gap junction channel pore, creating a funnel that restricts channel selectivity based on 
molecular size, flexibility, charge and charge distribution (Harris, 2007; Kwon et al., 
2011; Maeda et al., 2009).  In the non-sensory cells of the inner ear, Cx26 and Cx30 
intermix to form heteromeric and heterotypic channels (Ahmad et al., 2003; Forge et al., 
2003b; Marziano et al., 2003; Yum et al., 2007), and are also capable of forming 
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functional hemichannels (Gossman and Zhao, 2008; Zhao et al., 2005).  Through 
extrapolation, a mutation of the highly conserved hydrophilic T5 Cx30 amino acid (Grifa 
et al., 1999) may alter the permeability properties of both homotypic Cx30 and 
heterotypic Cx26/Cx30 channels.  Another possibility may be how the T5M mutant 
affects Cx26, as the role of Cx30 in hearing remains controversial (Boulay et al., 2013; 
Miwa et al., 2013), and increasing evidence suggests that Cx26 and Cx30 are co-
regulated (Boulay et al., 2013).  Expression levels of Cx26 were dramatically reduced in 
Cx30 knock-out (Boulay et al., 2013) and in Cx30 T5M knock-in mice that also exhibited 
decreased levels of Cx30 (Schutz et al., 2010).  Importantly, in the inner ear, this mutant 
may be affecting Cx26 levels, potentially reducing the frequency of heteromeric and 
heterotypic channel formation necessary for K
+
 recycling, however further investigation 
is necessary to clearly understand this relationship.   
2.4.2 The loss-of-function V37E mutant linked to Clouston and KID 
syndromes 
Although previously considered to be linked distinctly to Clouston syndrome (Common 
et al., 2002; Smith et al., 2002), the V37E mutant has now also been implicated in KID 
syndrome (Jan et al., 2004).  Other than the fact that the V37E mutant was retained in an 
unknown intracellular compartment (Common et al., 2002), little was known about this 
mutant.  Here, we conclusively show that the V37E mutant was retained within the ER, 
where it was possibly surveyed by molecular machinery as part of cellular quality control 
(Kleizen and Braakman, 2004).  Furthermore, this loss-of-gap junction channel and 
hemichannel function mutant acted in a (trans)dominant-negative fashion on co-
expressed Cx43, Cx26 and Cx30 and significantly induced UPR-mediated apoptosis in 
REKs, as indicated by up-regulated levels of ATF4 and CHOP. 
The V37E mutant is positioned in the 1
st
 transmembrane domain of Cx30.  According to 
the crystal structure of Cx26, the 1
st
 transmembrane domain is the major pore-lining helix 
involved in prominent intra-connexin interactions with all other transmembrane domains, 
which stabilizes the basic structure of the connexin subunit (Maeda et al., 2009).  In 
addition, the V37 amino acid is located in a valine-valine-alanine-alanine (VVAA) motif 
conserved between Cx26 and Cx30 (Maeda et al., 2009; Smith et al., 2002), and as 
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demonstrated by the V37I Cx26 mutant,  mutations within this particular motif reduce 
hexamer formation and channel function (Jara et al., 2012).  Importantly, the V37E Cx30 
mutation involves a more unique and critical substitution of a hydrophobic „valine‟ with 
an acidic „glutamic acid‟ residue, which we propose alters critical intra-connexin 
interactions and Cx30 stability, resulting in improper folding and protein accumulation in 
the ER.  In addition, various Cx26 mutants linked to Vohwinkel syndrome and PPK have 
been reported to exhibit dominant-negative and transdominant effects on other connexins, 
including Cx30 and Cx43 (Forge et al., 2003b; Marziano et al., 2003; Rouan et al., 2001).  
While V37E Cx30 may exhibit these effects on co-expressed wt Cx30, Cx26 and Cx43, it 
is also possible that V37E-mutant expressing cells undergoing apoptosis are internalizing 
these connexins, as has been reported for Cx43 (Kalvelyte et al., 2003).   
When the V37E mutant was expressed in keratinocytes, it induced apoptotic cell death 
through the activation of the UPR.  The UPR is a protective cellular mechanism regulated 
by luminal ER chaperone GRP78 (Malhotra and Kaufman, 2007), and is involved in 
normal keratinocyte differentiation (Sugiura et al., 2009) as well as normal lens 
development (Alapure et al., 2012).  Of note, mutations in Cx31 and Cx50 linked to 
erythrokeratoderma variabilis (EKV) and cataracts, respectively, induce an abnormal ER 
stress-mediated UPR (Alapure et al., 2012; Tattersall et al., 2009) which results in 
extensive cell death (Di et al., 2002; He et al., 2005).  While the expression of the V37E 
Cx30 mutant did not induce the up-regulation of GRP78, which may occur upon the 
activation of the ATF6 pathway (Berridge, 2002), the V37E mutant significantly induced 
the expression of ATF4 and CHOP involved in the PERK pathway of the UPR.  The 
induction of ATF4 and CHOP results in the activation of cell death-initiating caspases, 
including caspase-3, through the mitochondrial-dependent intrinsic cell death pathway 
(Galehdar et al., 2010; Groenendyk and Michalak, 2005; Malhotra and Kaufman, 2007).  
Although we identified the first Cx30 mutant to trigger UPR-mediated apoptosis, the 
apparent lack of GRP78 involvement suggests that further studies are necessary to 
determine if other cell death initiating pathways may also be involved. 
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2.4.3 The loss-of-function G59R mutant linked to Vohwinkel/Bart-
Pumphrey syndromes 
Here, a previously uncharacterized loss-of-function Cx30 G59R mutant was found to 
occasionally form gap junction plaques, but was mainly localized to the Golgi apparatus.  
This is consistent with findings for Vohwinkel syndrome-linked G59A and D66H Cx26 
mutants (Bakirtzis et al., 2003; Marziano et al., 2003; Thomas et al., 2004), suggesting 
that mutations in the 1
st
 extracellular domain of Cx30 and Cx26 may lead to similar 
disease phenotypes.  Supporting the essential role of the 1
st
 extracellular loop, the N45K 
Cx26 mutation located in this domain causes Bart-Pumphrey syndrome (Richard et al., 
2004).  The evolutionarily conserved 1st extracellular loop of Cx26 (and by extension 
Cx30) has been suggested to play a role in voltage gating (Tang et al., 2009; Verselis et 
al., 2009), and more importantly, inter-connexin and inter-connexon interactions (Maeda 
et al., 2009).  Therefore, the Cx30 G59R mutant may result in defective connexin 
oligomerization, which occurs primarily in the ER and Golgi apparatus for several 
connexins including  Cx32,  Cx26, Cx43 and Cx46 (Das Sarma et al., 2002; Evans et al., 
1999; Koval et al., 1997; Musil and Goodenough, 1993).  Reduced channel function at 
the cell surface may also indicate defective hemichannel docking, highlighting the 
importance of this domain in channel formation and function linked to hearing loss and 
skin diseases. 
2.4.4 The A88V mutant linked to Clouston syndrome 
The A88V mutant is one of four mutations linked to Clouston syndrome.  Previous 
studies localized the A88V mutant to intracellular compartments, although it could be 
partially rescued to the cell surface when co-expressed with wt Cx30 (Common et al., 
2002; Essenfelder et al., 2004).  In contrast, we demonstrated that a population of the 
A88V mutant formed gap junction-like structures at the cell surface and negatively 
affected Cx43-based gap junction coupling and the trafficking of both wt Cx26 and Cx30.  
In addition, the A88V mutant was previously found to exhibit abnormal hemichannel 
activity associated with adenosine triphosphate (ATP) release and subsequent cell death 
(Essenfelder et al., 2004).  We extended these studies by demonstrating that the A88V 
mutant significantly induced apoptosis, potentially accounting for the observed dominant-
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negative and transdominant effects as suggested for the V37E mutant, as well as induced 
the up-regulation of UPR protein ATF4.  While this suggests that the A88V mutant could 
be activating a slight UPR, we propose that it results in cell death and disease primarily 
via a UPR-independent pathway. 
Clearly, the A88 amino acid is critical for Cx30 hemichannel and channel function.  Cx30 
forms voltage-gated hemichannels (Valiunas and Weingart, 2000), which are normally 
closed under physiological conditions and open in response to low extracellular 
concentrations of Ca
2+
 and Mg
2+
 (De Vuyst et al., 2007; Tong et al., 2007; Verselis and 
Srinivas, 2008).  Importantly, leaky hemichannels resulting in cell death have been 
reported for a number of other connexin mutations (Gerido et al., 2007; Lee et al., 2009; 
Mese et al., 2011; Stong et al., 2006), and also for the A88V Cx26 mutation linked to 
KID syndrome (Mhaske et al., 2013).  The crystal structure of Cx26 suggests that part of 
the 2
nd
 transmembrane domain also lines the channel pore and is involved in intra-
connexin interactions with other domains that dictate specific protein conformation, 
including the amino terminus (Kwon et al., 2011; Maeda et al., 2009).  By analogy, it is 
possible that the A88V Cx30 mutation affects protein folding and stability, which may 
result in the retention of a population of this mutant in the ER and trigger a slight ER 
stress-mediated up-regulation of UPR proteins like ATF4.  However, we propose that it 
primarily alters important interactions that move the amino terminal domain away from 
the cytoplasmic entrance of the pore (Kwon et al., 2011; Maeda et al., 2009) to favour 
abnormal hemichannel activity.  Therefore, we propose that leaky A88V Cx30 
hemichannels primarily induced apoptosis in REKs. 
In conclusion, our present study characterized four Cx30 mutations linked to skin disease 
(A88V), hearing loss (T5M) and combinations of both (V37E and G59R).  Each mutation 
results in disease manifestations through distinct mechanisms ranging from a mutant that 
exhibits characteristics similar to wild-type Cx30 (T5M), to mutants that induce apoptosis 
through activation of the UPR pathway (V37E, A88V) or potentially via abnormal 
hemichannel activity (A88V).  Importantly, we discovered the first Cx30 mutation to 
induce UPR-mediated apoptosis, which may provide insight into how patients with the 
V37E mutation may develop KID syndrome and not Clouston syndrome, which is linked 
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to the A88V mutation.  Thus, both V37E and A88V mutants cause similar skin 
phenotypes and induce apoptosis, but through different mechanisms.  In addition, the 
loss-of-function G59R mutant causes yet another skin disease phenotype, a combination 
of Vohwinkel and Bart-Pumphrey syndromes.  While all of these Cx30 autosomal 
dominant gene mutations cause syndromic and non-syndromic disease by different 
mechanisms, future studies will be needed to determine the key role of co-regulated 
connexins in the cochlea and epidermis.   
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Chapter 3  
3 General Discussion 
Effective GJIC plays an important role in regulating a number of cellular processes that 
contribute to normal tissue function and homeostasis, and defective GJIC has been linked 
to a number of diseases (Laird, 2006).  Alterations in GJIC are caused by mutations in 
connexins, the building blocks of hemichannels and gap junction channels (Bruzzone et 
al., 1996; Goodenough et al., 1996).  Even single amino acid substitutions may affect any 
aspect of connexin trafficking, channel formation, channel function or overall connexin 
stability.  Important to this particular study, defective GJIC in the epidermis and the 
cochlea results in various skin diseases and hearing loss (Nickel and Forge, 2008; 
Rabionet et al., 2002; Thomas et al., 2003; Zhao et al., 2006), as proper intercellular 
communication contributes to the continuous process of epidermal differentiation as well 
as sound transduction (Kikuchi et al., 2000; Langlois et al., 2007; Richard, 2000; Zhang 
et al., 2005).  In particular, Cx30 is highly expressed in both the inner ear and the 
epidermis (Di et al., 2001; Forge et al., 2003a; Kretz et al., 2004; Nickel and Forge, 
2008), and Cx30 mutations result in skin disease, hearing loss or syndromic diseases 
involving both (Baris et al., 2008; Chen et al., 2010; Essenfelder et al., 2004; Grifa et al., 
1999; Jan et al., 2004; Nemoto-Hasebe et al., 2009; Smith et al., 2002; Wang et al., 2011; 
Zhang et al., 2003). 
We investigated four different Cx30 mutants (T5M, V37E, G59R and A88V), each 
located in a specific protein domain, and hypothesized that each mutant results in disease 
through a distinct mechanism (Table 3.1).  By examining the subcellular localization and 
function of each mutant in GJIC-competent REKs and connexin-deficient HeLa cells, we 
discovered that the T5M mutant linked to non-syndromic hearing loss formed functional 
gap junctions and hemichannels between apposing cells, while the V37E and G59R 
mutants that cause KID syndrome and Vohwinkel/Bart-Pumphrey syndromes, 
respectively, were retained in intracellular compartments and were non-functional.  In 
particular, the G59R mutant localized to the Golgi apparatus, with some evidence of gap 
junction formation at the cell surface, while the V37E mutant was localized only to the 
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Table 3.1:  Summary of Cx30 mutants linked to skin diseases and non-syndromic 
hearing loss.   
This table outlines four Cx30 mutants linked to non-syndromic hearing loss as well as 
Clouston, Vohwinkel, Bart-Pumphrey and KID syndromes in terms of their localization, 
function, ability to induce UPR-mediated apoptosis and propensity to exhibit dominant-
negative/transdominant effects on ectopically co-expressed wild type connexins. 
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ER.  In addition, we determined that the A88V mutant associated with Clouston 
syndrome, as well as the V37E mutant, significantly induced apoptosis in REKs.  Further 
examination revealed that V37E mutant expression resulted in the up-regulation of UPR-
related proteins, ATF4 and CHOP, while A88V mutant expression resulted in a less 
pronounced up-regulation of ATF4 only.  When examining the effects of Cx30 mutants 
on other connexins in REKs, the V37E and A88V mutants impaired the delivery of wild-
type Cx26 and Cx30 to the cell surface, potentially contributing to how these mutants 
cause different disease characteristics. 
Cx30 and Cx26 share 76% sequence homology (Grifa et al., 1999), allowing for 
inferences to be made about the function of Cx30 domains based on what has been 
reported for Cx26, as its crystal structure has recently been determined (Kwon et al., 
2011; Maeda et al., 2009).  First, the T5 amino acid is located in the flexible amino 
terminal domain that lines the channel pore, restricting the pore diameter and channel 
permeability.  Normally in a Cx26 hemichannel, a funnel-stabilizing, circular network of 
hydrogen bonds forms between the A2 amino acids and their neighbouring T5 amino 
acids, however, a threonine to methionine substitution (T5M) that introduces a sulphur-
containing amino acid, most likely disrupts this network and alters channel permeability 
(Maeda et al., 2009).  Given that cells in vivo are expected to co-express wild-type Cx30 
and the T5M mutant, Cx30-containing hemichannels could be composed of all wild-type 
Cx30 or T5M subunits as well as a mixture of both, which may explain why some studies 
have shown that the T5M mutant is capable of passing electrical current but not 
metabolic molecules (Schutz et al., 2010; Zhang et al., 2005), while others have described 
it as completely non-functional (Grifa et al., 1999).  Although we did not examine the 
electrical coupling capacity of the T5M mutant, our results indicate that the T5M mutant 
was permeable to Alexa 350, a small molecular dye.  Secondly, the V37 amino acid is 
located in the 1
st
 transmembrane domain, which plays a critical role in protein 
conformation and stability (Maeda et al., 2009).  The V37E Cx30 mutant may alter 
interactions within a connexin subunit, resulting in an unstable protein conformation that 
prevents its export out of the ER, and triggers the UPR that we observed in REKs.  A 
similar mutant in Cx26, V37I linked to non-syndromic hearing loss, exhibited reduced 
gap junction function and formed non-functional hemichannels (Jara et al., 2012), 
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indicating that the 1
st
 transmembrane domain is not only important for protein stability, 
but also channel function at the cell surface.  Thirdly, the G59 amino acid is located in 
the 1
st
 extracellular loop, which has been suggested to be involved in oligomerization and 
hemichannel docking.  In particular, hydrogen bonds form between the N54 and L56 
amino acids in apposing connexins, as well as between apposing G57 amino acids 
(Maeda et al., 2009), stabilizing the docked hemichannel conformation.  Similar to the 
G59R Cx30 mutant, the G59R, G59S and G59A Cx26 mutants result in many of the 
same symptoms (Alexandrino et al., 2005; Heathcote et al., 2000; Leonard et al., 2005), 
and consistent with our results for G59R Cx30, studies have shown that the G59A Cx26 
mutant was non-functional and retained primarily in the Golgi apparatus (Marziano et al., 
2003; Thomas et al., 2004).  The G59R Cx30 mutant introduces a relatively large 
amine/amide-containing side chain compared to glycine, which could affect steric 
interactions involved in oligomerization and hemichannel docking, resulting in its 
retention in the Golgi and loss of function at the cell surface.  Lastly, the A88 amino acid 
is located in the 2
nd
 transmembrane domain, which may partially dictate protein stability, 
oligomerization and channel permeability (Maeda et al., 2009).  The A88V Cx30 mutant 
may disrupt normal protein conformation and result in some retention in the ER, 
potentially accounting for the slight UPR we observed.  While the localization of the 
A88V mutant remains unclear, we demonstrated that a population successfully trafficked 
to the cell surface.  We were unable to perform functional studies with the A88V Cx30 
mutant in HeLa cells or REKs, as its expression rapidly induced apoptosis in both cell 
lines.  In previous studies, the A88V Cx30 Clouston syndrome-linked and A88V Cx26 
KID syndrome-linked mutants both formed leaky hemichannels and resulted in cell death 
(Essenfelder et al., 2004; Mhaske et al., 2013), highlighting the importance of the A88 
amino acid in channel permeability and function.  Collectively, connexin point mutations 
may displace important interactions necessary to maintain proper GJIC.  In particular, 
Cx26 and Cx30 mutations alter epidermal and cochlear homeostasis, resulting in various 
syndromic skin diseases and hearing loss. 
Previous studies suggest that K
+
 recycling through GJIC is important for hearing (Hibino 
and Kurachi, 2006; Kikuchi et al., 2000; Zhang et al., 2005; Zhao et al., 2006).  Most gap 
junction channels in the cochlear epithelial and connective tissue gap junction systems 
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are composed of Cx26 and Cx30, which are capable of forming mixed channels (Ahmad 
et al., 2003; Forge et al., 2003a; Forge et al., 2003b; Marziano et al., 2003; Yum et al., 
2007; Zhao and Santos-Sacchi, 2000).  A great deal of research focuses on the 
involvement of these connexins in sound transduction, as mutations in Cx26 and Cx30 
account for nearly 50% of all prelingual non-syndromic hearing loss cases (Ahmad et al., 
2007; Chang et al., 2008; Cohen-Salmon et al., 2002; Schutz et al., 2010).  During 
cochlear development in mice, the absence of Cx30 or the ablation of Cx26 from the 
epithelial gap junction network had no effect on cochlear morphology, indicating that 
GJIC may not play a critical role in the developing cochlea (Cohen-Salmon et al., 2002; 
Teubner et al., 2003).  However, further studies revealed that both types of mice were 
deaf due to the lack of normal endolymphatic K
+
 levels and EP, which resulted in sensory 
cell and supporting cell apoptosis.  Initially, these studies elucidated the importance of 
both Cx26 and Cx30 in sound transduction, rather than cochlear development, however 
more recent studies indicate that the role of Cx30 remains controversial.  Increasing 
evidence supports the notion that Cx26 and Cx30 are co-regulated, as both genes are 
located within 50 kilobases of each other on chromosome 13 (Ortolano et al., 2008).  In 
particular, the down-regulation of Cx26 in Gjb6
-/-
mice (referred to as Cx30
-/-
 mice in this 
thesis), originally described by Teubner et al. (2003), was suggested to be the cause of 
hearing loss (Ahmad et al., 2007; Boulay et al., 2013; Ortolano et al., 2008), implying 
that Cx26 expression rather than Cx30 expression is critical for hearing.  However, 
Chang et al. (2008) described that while Cx30
-/-
 mice exhibited normal ionic coupling 
due to sufficient expression of Cx26, biochemical coupling was drastically reduced, 
indicating that Cx30 channels may be necessary for the proper transfer of metabolites or 
secondary messengers.  Schutz et al. (2010) generated a T5M Cx30 mutant knock-in 
mouse, which upon investigation, was found to be mildly deaf and exhibit decreased 
expression of both Cx26 and Cx30 in the cochlea.  The T5M mutation was inserted by 
homologous recombination into mouse embryonic stem cells, and its expression was 
controlled by the endogenous Cx30 promoter (Schutz et al., 2010).  Consistent with our 
results in REKs, T5M Cx30 trafficked to the cell surface of cochlear supporting cells. 
However, in contrast, functional studies indicated that while ionic coupling was normal, 
biochemical coupling was reduced (Schutz et al., 2010), similar to Cx30
-/-
 mice described 
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by Chang et al. (2008).  In addition, mixed gap junction channels have been reported to 
facilitate the transfer of molecules that would not normally permeate through their 
homotypic counterparts (Ayad et al., 2006; Beyer et al., 2001; Yum et al., 2007), and 
Cx26/Cx30 mixed channels are able to pass biochemical molecules twice as fast as their 
homotypic Cx26 or Cx30 relatives (Sun et al., 2005), favouring the notion that Cx30 may 
play an important role in hearing through the formation of mixed channels.  Collectively, 
the involvement of Cx30 in hearing remains controversial. 
3.1 Conclusions and Future Directions 
In conclusion, connexin mutations that affect trafficking, channel formation, channel 
function and protein expression, can drastically affect GJIC and disrupt normal tissue 
function and homeostasis.  In particular, our study demonstrated how specific Cx30 
mutations linked to non-syndromic hearing loss (T5M) and various skin diseases (V37E, 
G59R and A88V), resulted in disease through distinct mechanisms.  However, future 
studies are essential for expanding our knowledge of how Cx30 mutants affect certain 
tissues and are linked to specific diseases, while the normal functioning of Cx30 
maintains tissue homeostasis and facilitates disease prevention. 
To further establish the roles of ER stress and the UPR in apoptosis linked to the V37E 
and A88V Cx30 mutants, we would first examine the expression levels of a number of 
ER-resident chaperone proteins, including GRP94, calreticulin and PDI, which are 
induced during ER stress as a result of the UPR (Berridge, 2002).  Since we discovered 
that ATF4 is up-regulated by the V37E and A88V mutants, we would also further dissect 
the potential role of the PERK pathway by investigating whether the alpha subunit of 
eukaryotic translation initiation factor 2 (eIF2α) was phosphorylated, an event preceeding 
the up-regulation of ATF4 that results in transient mRNA translation attenuation to 
alleviate ER stress (Malhotra and Kaufman, 2007).  In addition, investigation of the IRE1 
and ATF6 pathways of the UPR would indicate if the expression of V37E and A88V 
mutants simultaneously activated multiple arms of the UPR.  Collectively, these studies 
would contribute to our knowledge of how these particular mutants are linked to different 
disease characteristics. 
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In our studies, Cx30 mutants were transiently expressed in REKs, and we discovered that 
the V37E and A88V mutants rapidly induced cell death as early as 18 hours following 
transfection.  All of our studies were carried out 24 hours after transfection, and since 
A88V mutant-expressing cells in particular were undergoing extensive cell death at this 
time, it was difficult to perform localization and functional studies.  Therefore, the 
generation of an inducible expression system would allow us to perform a number of time 
course localization and functional studies with this particular mutant, as well as the V37E 
mutant, immediately following expression and prior to cell death.  Using this system may 
also help to establish a clearer image of the UPR pathways associated with the V37E and 
A88V mutants. 
While these future directions would allow us to examine Cx30 mutants at the cellular 
level, more relevant models would significantly contribute to understanding the 
mechanisms underlying Clouston, Vohwinkel, Bart-Pumphrey and KID syndromes.  
REKs are unique in their ability to stratify into 3D organotypic epidermis, a model 
system previously used to observe the expression levels and roles of certain connexins 
during epidermal differentiation, as well as the effects of mutant connexins on the 
formation of distinct epidermal strata (Langlois et al., 2007; Maher et al., 2005; Thomas 
et al., 2007).  Previously, Thomas et al. (2007) observed the effects of the D66H and 
G59A Cx26 mutants, linked to Vohwinkel syndrome and PPK, on the growth and 
differentiation of organotypic epidermis.  As previously mentioned, we demonstrated that 
the G59R Cx30 mutant behaves similar to the G59A Cx26 mutant in REKs.  Thus, it 
would be beneficial to observe whether the G59R Cx30 mutant would affect epidermal 
differentiation, as the G59A Cx26 mutant had no effect on the differentiation of 
organotypic epidermis (Thomas et al., 2007).  Since this technique requires the 
generation of stable mutant-expressing keratinocytes (Langlois et al., 2007; Thomas et 
al., 2007), our model would not be suitable for V37E and A88V Cx30 mutants that 
induced apoptosis in REKs as early as 18 hours post-transfection.   
Cx26 mutants linked to Vohwinkel syndrome (D66H) and lethal KID syndrome (S17F 
and G45E) have previously been studied in mouse models (Bakirtzis et al., 2003; Mese et 
al., 2011; Schutz et al., 2011).  In engineered mutant mice, the S17F mutant was 
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conditionally expressed (Schutz et al., 2011), while the D66H and G45E mutants were 
expressed only in epidermal keratinocytes (Bakirtzis et al., 2003; Mese et al., 2011).  
While homozygous S17F Cx26 mice were not viable, heterozygous mice were smaller 
than their wt littermates and exhibited increased epidermal proliferation of tail and foot 
skin (Schutz et al., 2011).  D66H Cx26 mutant mice exhibited keratoderma shortly after 
birth as a result of thickened cornified layers and extensive apoptosis, indicating 
premature programmed keratinocyte cell death (Bakirtzis et al., 2003).  Mice harbouring 
the G45E Cx26 mutant were less viable and developed a number of hyperproliferative 
skin abnormalities, which were associated with abnormal hemichannel activity in 
cultured mutant primary keratinocytes (Mese et al., 2011).  These mouse models 
elucidated the effects of Cx26 mutants on overall epidermal differentiation and function 
in an in vivo setting.  Therefore, the generation of V37E, A88V and even G59R Cx30 
knock-in mutant mouse models, in a similar fashion as described by Schutz et al. (2010), 
would provide critical insight into the mechanisms behind Cx30-linked skin diseases.  In 
particular, since we demonstrated that V37E and A88V Cx30 mutants induced cell death 
in REKs, generation of these mice would allow us to observe how premature cell death 
affects epidermal integrity and differentiation in a more relevant model system.  
Importantly, the G59R mutant mouse may also provide us with insight into why patients 
experience pseudoainhum.  Furthermore, while the T5M Cx30 knock-in mouse (Schutz et 
al., 2010) contributes to our knowledge of how the T5M mutant is linked to non-
syndromic hearing loss, little is known about the mechanisms underlying hearing loss in 
Vohwinkel, Bart-Pumphrey and KID syndromes caused by Cx30 mutations.  Developing 
these knock-in mutant mice would expand our knowledge of how these mutations disrupt 
GJIC involved in normal cochlear and epidermal homeostasis in an in vivo setting, and 
would contribute to determining the functional roles of Cx30 in hearing and epidermal 
differentiation. 
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